0001299130-23-000032 | 10-K | XBRL Viewer | Pacific Biosciences OF California INC

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Jan. 31, 2023	Jun. 30, 2022
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Transition Report	false
Entity File Number	001-34899
Entity Registrant Name	Pacific Biosciences of California, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	16-1590339
Entity Address, Address Line One	1305 O’Brien Drive
Entity Address, City or Town	Menlo Park
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94025
City Area Code	650
Local Phone Number	521-8000
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PACB
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 991,868,509
Entity Common Stock Shares Outstanding		247,079,374
Amendment Flag	false
Entity Central Index Key	0001299130
Document Fiscal Period Focus	FY
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement relating to its 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
Auditor Name	Ernst & Young LLP
Auditor Location	San Mateo, California
Auditor Firm Id	42

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 325,089	$ 460,725
Investments	447,229	583,675
Accounts receivable, net	18,786	24,241
Inventory, net	50,381	24,599
Prepaid expenses and other current assets	10,289	7,394
Short-term restricted cash	300	500
Total current assets	852,074	1,101,134
Property and equipment, net	41,580	32,504
Operating lease right-of-use assets, net	39,763	46,617
Long-term restricted cash	2,922	4,592
Intangible assets, net	410,245	410,979
Goodwill	409,974	409,974
Other long-term assets	10,528	1,170
Total assets	1,767,086	2,006,970
Current liabilities
Accounts payable	12,028	11,002
Accrued expenses	32,596	36,261
Deferred revenue, current	30,498	10,977
Operating lease liabilities, current	8,886	7,710
Other liabilities, current	7,233	5,759
Contingent consideration liability, current	172,094
Total current liabilities	263,335	71,709
Deferred revenue, non-current	1,794	25,049
Contingent consideration liability, non-current		169,717
Operating lease liabilities, non-current	41,070	49,970
Convertible senior notes, net, non-current	896,683	896,067
Other liabilities, non-current	1,300	3,471
Total liabilities	1,204,182	1,215,983
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding
Common stock, $0.001 par value: Authorized 1,000,000 shares; issued and outstanding 226,505 and 220,978 shares at December 31, 2022 and December 31, 2021, respectively	227	221
Additional paid-in capital	2,099,782	2,009,945
Accumulated other comprehensive loss	(4,765)	(1,087)
Accumulated deficit	(1,532,340)	(1,218,092)
Total stockholders' equity	562,904	790,987
Total liabilities and stockholders' equity	$ 1,767,086	$ 2,006,970

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2010
Condensed Consolidated Balance Sheets [Abstract]
Preferred Stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, shares authorized	50,000,000	50,000,000	50,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001	$ 0.001
Common Stock, shares authorized	1,000,000,000	1,000,000,000	1,000,000,000
Common Stock, shares issued	226,505,000	220,978,000
Common Stock, shares outstanding	226,505,000	220,978,000

Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 128,304,000	$ 130,513,000	$ 78,893,000
Cost of Revenue:
Amortization of intangible assets	733,000	306,000
Loss on purchase commitment	3,705,000
Total cost of revenue	79,269,000	71,653,000	46,327,000
Gross profit	49,035,000	58,860,000	32,566,000
Operating Expense:
Research and development	193,000,000	112,899,000	64,152,000
Sales, general and administrative	160,854,000	124,124,000	72,799,000
Merger-related expenses		31,129,000
Change in fair value of contingent consideration	2,377,000	1,143,000
Total operating expense	356,231,000	269,295,000	136,951,000
Operating loss	(307,196,000)	(210,435,000)	(104,385,000)
Gain from Reverse Termination Fee from Illumina			98,000,000
(Loss)/Gain from Continuation Advances from Illumina		(52,000,000)	34,000,000
Interest expense	(14,690,000)	(12,530,000)	(267,000)
Other income, net	7,638,000	93,000	2,055,000
(Loss) income before benefit from income taxes	(314,248,000)	(274,872,000)	29,403,000
Benefit from income taxes		(93,649,000)
Net (loss) income	(314,248,000)	(181,223,000)	29,403,000
Other comprehensive (loss) income:
Unrealized (loss) gain on investments	(3,678,000)	(1,172,000)	80,000
Comprehensive (loss) income:	$ (317,926,000)	$ (182,395,000)	$ 29,483,000
Net (loss) income per share:
Basic	$ (1.40)	$ (0.89)	$ 0.18
Diluted	$ (1.40)	$ (0.89)	$ 0.17
Weighted average shares outstanding used in calculating net (loss) income per share:
Basic	224,550	204,136	165,187
Diluted	224,550	204,136	174,970
Product [Member]
Revenue:
Total revenue	$ 108,699,000	$ 113,505,000	$ 65,424,000
Cost of Revenue:
Cost of product revenue	60,932,000	56,358,000	35,424,000
Service and Other [Member]
Revenue:
Total revenue	19,605,000	17,008,000	13,469,000
Cost of Revenue:
Cost of service and other revenue	$ 13,899,000	$ 14,989,000	$ 10,903,000

Consolidated Statements of Stockholders’ Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member] Revision of Prior Period, Accounting Standards Update, Adjustment [Member]	Accumulated Deficit [Member]	Revision of Prior Period, Accounting Standards Update, Adjustment [Member]	Total
Balance at Dec. 31, 2019	$ 153	$ 1,120,999	$ 5		$ (1,066,240)		$ 54,917
Balance, shares at Dec. 31, 2019	153,119
Net (loss) income					29,403		29,403
Other comprehensive gain (loss)			80				80
Issuance of common stock in conjunction with equity plans	$ 10	46,350					46,360
Issuance of common stock in conjunction with equity plans, shares	9,819
Issuance of common stock from Underwritten Public Equity Offerings, net of issuance costs	29,356
Issuance of common stock from underwritten Public Equity Offering, net of issuance costs	$ 29	187,201					187,230
Share-based compensation expense		17,533					17,533
Balance (ASC 326 adoption effect [Member]) at Dec. 31, 2020				$ (32)		$ (32)
Balance at Dec. 31, 2020	$ 192	1,372,083	85		(1,036,869)		335,491
Balance, shares at Dec. 31, 2020	192,294
Net (loss) income					(181,223)		(181,223)
Other comprehensive gain (loss)			(1,172)				(1,172)
Issuance of common stock in conjunction with equity plans	$ 9	31,797					31,806
Issuance of common stock in conjunction with equity plans, shares	8,557
Issuance of common stock in Private Placement, net of issuance costs	$ 11	294,834					294,845
Issuance of common stock in Private Placement, net of issuance costs, Shares	11,215
Issuance of common stock in acquisition of Omniome	$ 9	237,876					237,885
Issuance of common stock in acquisition of Omniome, shares	8,912
Share-based compensation expense		73,355					73,355
Balance at Dec. 31, 2021	$ 221	2,009,945	(1,087)		(1,218,092)		$ 790,987
Balance, shares at Dec. 31, 2021	220,978						220,978
Net (loss) income					(314,248)		$ (314,248)
Other comprehensive gain (loss)			(3,678)				(3,678)
Issuance of common stock in conjunction with equity plans	$ 6	11,224					11,230
Issuance of common stock in conjunction with equity plans, shares	5,527
Share-based compensation expense		78,613					78,613
Balance at Dec. 31, 2022	$ 227	$ 2,099,782	$ (4,765)		$ (1,532,340)		$ 562,904
Balance, shares at Dec. 31, 2022	226,505						226,505

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net (loss) income	$ (314,248)	$ (181,223)	$ 29,403
Adjustments to reconcile net loss to net cash used in operating activities
Loss (gain) from Continuation Advances		52,000	(34,000)
Depreciation	9,480	7,199	6,428
Amortization of intangible	913	381
Amortization of right-of-use assets	6,925	4,005	2,876
Amortization of debt discount and financing costs	640	539	129
Share-based compensation	78,613	73,355	17,533
Amortization of premium and accretion of discount on marketable securities, net	(244)	4,011	(107)
Change in the estimated fair value of contingent consideration	2,377	1,143
Inventory provision	6,027	678	527
Loss on disposition of equipment	278	54
Deferred income taxes		(93,649)
Changes in assets and liabilities
Accounts receivable, net	5,455	(7,166)	(1,603)
Inventory, net	(33,906)	(13,109)	(1,623)
Prepaid expenses and other assets	(12,324)	(1,024)	(1,063)
Accounts payable	1,025	6,363	(5,072)
Accrued expenses	(3,651)	15,320	4,102
Deferred revenue	(3,734)	25,736	729
Operating lease liabilities	(7,724)	(4,990)	(3,802)
Other liabilities	887	(803)	5,046
Net cash (used in) provided by operating activities	(263,211)	(111,180)	19,503
Cash flows from investing activities
Purchase of property and equipment	(16,750)	(5,931)	(1,039)
Addition of intangible assets	(179)
Purchase of investments	(442,788)	(988,046)	(373,283)
Sales of investments		212,734	1,400
Maturities of investments	575,800	422,505	153,600
Net cash provided by (used in) investing activities	116,083	(678,531)	(219,322)
Cash flows from financing activities
Continuation Advances		(52,000)	34,000
Proceeds from issuance of Convertible Senior Notes, net of issuance costs		895,536
Proceeds from issuance of common stock under equity offerings, net of issuance costs		294,845	187,479
Proceeds from issuance of common stock from equity plans	11,230	31,806	46,360
Notes payable principal payoff	(1,608)	(361)	(16,000)
Other		(245)
Net cash provided by financing activities	9,622	1,169,581	251,839
Net (decrease) increase in cash, cash equivalents, and restricted cash	(137,506)	379,870	52,020
Cash, cash equivalents, and restricted cash at beginning of period	465,817	85,947	33,927
Cash, cash equivalents, and restricted cash at end of period	328,311	465,817	85,947
Cash and cash equivalents at end of period	325,089	460,725	81,611
Restricted cash at end of period	3,222	5,092	4,336
Supplemental disclosure of cash flow information
Interest Paid	14,049	6,928	491
Supplemental disclosure of non-cash investing and financing activities
Inventory transferred to property and equipment	2,812	2,586	1,097
Property and equipment transferred to inventory	$ (715)	(383)	$ (919)
Right-of-use asset and liability additions and modifications		2,576
Issuance of common stock in acquisition of Omniome		237,885
Circulomics, Inc [Member]
Cash flows from investing activities
Cash paid for purchase of business acquisition, net of cash acquired		(28,560)
Omniome, Inc [Member]
Cash flows from investing activities
Cash paid for purchase of business acquisition, net of cash acquired		$ (291,233)

Organization and Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Organization and Significant Accounting Policies [Abstract]

Organization and Significant Accounting Policies

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Business Overview

We are a life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our existing HiFi long-read sequencing technology and our emerging short-read Sequencing by Binding (SBB^®) technology. Our products address solutions across a broad set of applications including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.

References in this report to “PacBio,” “we,” “us,” the “Company,” and “our” refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.

Basis of Presentation and Consolidation

Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions and ongoing COVID-19 pandemic on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December 31, 2022. Actual results could differ materially from these estimates.

Functional Currency

The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statement of operations and comprehensive (loss) income.

Cash, Cash Equivalents, Restricted Cash, and Investments

We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies’ securities.

We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive (loss) income in stockholders’ equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net.

Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.

Restricted cash includes cash that is not readily available for use in the Company’s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.

Concentration and Other Risks

Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December 31, 2022, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.

Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers’ financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivable including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer’s ability to pay. We have not experienced any significant credit losses to date.

Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors.

For the years ended December 31, 2022, 2021, and 2020, one customer accounted for approximately 12%, 13%, and 14% of our total revenue, respectively.

As of December 31, 2022 and 2021, 57% and 53% of our accounts receivable were from domestic customers, respectively. As of December 31, 2022, one customer represented approximately 10% of our net accounts receivable. As of December 31, 2021, no customer represented 10% or greater of our net accounts receivable.

We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements.

Inventory, Net

Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (“FIFO”) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs while determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories.

We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.

Property and Equipment, Net

Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.

Estimated useful lives of the major classes of property and equipment are as follows:



		Estimated Useful Lives
Leasehold improvements		3 to 10 years
Lab equipment		3 to 5 years
Computer equipment		3 to 5 years
Computer software		3 years
Furniture and fixtures		3 to 5 years

Operating Leases

We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred.

Business Combinations

Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.

In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense in our consolidated statements of operations and comprehensive (loss) income.

If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.

Goodwill, Intangible Assets, and Other Long-Lived Assets

Assets acquired, including intangible assets and capitalized in-process research and development (“IPR&D”), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&D asset is expensed in the period of abandonment.

Goodwill and IPR&D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill in the second quarter of each year and IPR&D in the fourth quarter of each year, or more frequently if indicators of potential impairment exist.

We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.

During the IPR&D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&D with the carrying value. If the carrying amount of the IPR&D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.

Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.

Revenue Recognition

Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.

We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods, or services is transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

Our instrument sales are generally sold in a bundled arrangement and commonly include the instrument, instrument accessories, training, and consumables. For such bundled arrangements, we account for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. Installation services are considered distinct from the instrument. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers.

The consideration for bundled arrangements is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities.

Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option

to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it as a separate performance obligation when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. We may also utilize the alternative approach to estimate the standalone selling price, available pursuant to the applicable accounting guidance, to the extent we conclude the applicable criteria for using the alternative approach has been met. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change.

Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.

Cost of Revenue

Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.

Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.

Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base.

Research and Development

Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.

Credit Losses

Trade accounts receivable

The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer’s ability to pay. Credit loss expense was immaterial for the years ended December 31, 2022 and 2021.

Available-for-sale debt securities

Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income. The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.

Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of the COVID-19 pandemic, or other customer-specific factors.

Income Taxes

We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized.

We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions.

Share-based Compensation

We account for share-based payments using a fair-value based method for costs related to all share-based payments, including stock options, restricted stock units, and stock issued under our employee stock purchase plan (“ESPP”). We estimate the fair value of share-based payment awards that are stock options and issued under our ESPP on the date of grant using an option-pricing model. See Note 10. Stockholders’ Equity for further information regarding share-based compensation.

Other Comprehensive (Loss) Income

Other comprehensive (loss) income is comprised of unrealized (losses) gains on our investment securities.

Shipping and Handling

Costs related to shipping and handling are included in cost of revenues for all periods presented.

Earnings per Share

Basic net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method.

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

There are no accounting standards updates (“ASUs”) that have been recently adopted and are applicable to our consolidated financial statements.

Accounting Pronouncements Pending Adoption

In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This authoritative guidance will be effective for us in the first quarter of 2023. The adoption of this guidance is not expected to have a material effect on our consolidated financial statements.

Business Acquisitions

12 Months Ended

Dec. 31, 2022

Business acquisitions [Abstract]

Business Acquisitions

NOTE 2. BUSINESS ACQUISITIONS

Omniome, Inc.

On September 20, 2021, we completed our acquisition of Omniome, Inc. (“Omniome”), a San Diego-based company, to obtain their proprietary short-read DNA sequencing platform capable of delivering high accuracy (the “Omniome acquisition”).

In connection with the Omniome acquisition, all outstanding equity securities of Omniome were cancelled in exchange for approximately $315.7 million in cash, 8,911,580 shares of our common stock with a fair value of $249.4 million and contingent consideration with a fair value of $168.6 million. The fair value of the 8,911,580 common shares issued was determined based on the closing market price of PacBio’s common shares on the acquisition date.

In addition, approximately $18.9 million, comprised of $7.4 million of cash, 226,811 shares of our common stock with a fair value of $6.3 million, and $5.2 million related to contingent consideration, was accounted for as a one-time post acquisition share-based compensation expense. This share-based compensation expense was due to accelerated vesting of Omniome stock awards in connection with the acquisition.

In connection with the acquisition the contingent consideration of $200 million (composed of $100 million in cash and $100 million in shares of our common stock) is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes SBB technology. The number of shares of stock to be issued will be determined using the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that is two days immediately prior to the achievement of the milestone. Of the $100 million in shares of our common stock to be issued as part of the milestone, $4.1 million was attributable to stock options issued by PacBio in replacement of Omniome’s unvested options as part of the transaction. Upon achievement of the milestone, shares will be issued not in excess of an amount equal to 19.9% of our outstanding shares of common stock on the date of closing (prior to the issuance of any shares issued in connection with the transaction or the related private placement), less 11,500,000 shares.

The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our Consolidated Statements of Operations and Comprehensive Loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a scenario-based method that considers a range of possible outcomes and their assigned probabilities of occurrence. The potential outcomes are discounted to present value at a discount rate equal to the sum of the term-matched risk-free-interest rate plus PacBio’s credit spread.

Total consideration transferred for the acquisition is as follows (in thousands):


Total cash paid	$	315,703
Fair value of share consideration		249,435
Fair value of contingent consideration		168,574
Less: Share-based compensation expense excluded from consideration transferred		(18,923)
Total consideration transferred	$	714,789

The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. As of December 31, 2021, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):


Cash and cash equivalents	$	15,338
Property and equipment, net		6,123
Operating lease right-of-use assets, net		18,095
In-process research and development ("IPR&D")		400,000
Goodwill		390,665
Other assets		3,203
Deferred income tax liability		(91,814)
Liabilities assumed		(26,821)
Total consideration transferred	$	714,789

During the year ended December 31, 2021, we recorded a measurement period adjustment of $1.6 million to decrease goodwill and a corresponding $0.4 million to decrease the deferred tax liability on the Consolidated Balance Sheet, and a $1.2 million decrease to our benefit from income taxes on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The measurement period adjustment was due to new information that became available to us upon the completion of the IRC Section 382 Tax Study, where we identified additional net operating losses that are available to us from acquired assets. Refer to Note 9 – Income Taxes, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2021 for more information. There were no measurement period adjustments recorded in the year ended December 31, 2022.

The goodwill recognized was primarily attributable to the assembled workforce and synergies that are expected to occur from the integration of Omniome and is not deductible for income tax purposes.

We incurred costs related to the Omniome acquisition of approximately $12.0 million during the twelve months ended December 31, 2021, which are included in merger-related costs on the Consolidated Statement of Operations and Comprehensive (Loss) Income. No significant merger-related costs were incurred during the twelve months ended December 31, 2022.

The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if Omniome had been acquired as of the beginning of 2020, giving effect on a pro forma basis to the purchase accounting adjustments such as $12.0 million of PacBio acquisition-related costs, $18.9 million of share-based compensation expense related to acceleration of certain Omniome stock options not attributable to pre-combination service, and a $91.0 million one-time income tax benefit from the reduction of our deferred tax asset valuation allowance resulting from the Omniome acquisition, as well as a pro forma adjustment to reflect $16.7 million of Omniome’s acquisition-related costs.

The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of the consolidated results of the combined business had the acquisition actually occurred at the beginning of 2020 or the results of future operations of the combined business.

The following table summarizes the unaudited pro forma financial information:


	Years Ended December 31,
(in thousands, except per share amounts)	2021		2020
Pro forma total revenue	$	130,513	$	78,893
Pro forma net (loss) income	$	(278,451)	$	17,510
Pro forma net (loss) income per share - basic and diluted	$	(1.27)	$	0.09

Our consolidated financial statements include the results of operations for Omniome beginning September 20, 2021. Revenues of $0 and a net loss of $15.6 million from the acquired Omniome business have been included in our Consolidated Statement of Operations and Comprehensive (Loss) Income for the twelve months ended December 31, 2021.

Circulomics, Inc.

On July 20, 2021, we acquired Circulomics Inc. (“Circulomics”), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows (the “Circulomics acquisition”).

We paid $29.5 million in cash in exchange for all outstanding shares of common stock of Circulomics. We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on their respective fair values at the date of the completion of the Circulomics acquisition. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):


Cash and cash equivalents	$	987
Property and equipment, net		214
Intangible assets		11,360
Goodwill		19,309
Other assets		467
Deferred income tax liability		(2,672)
Liabilities assumed		(118)
Total consideration transferred	$	29,547

The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $19.3 million, which is primarily attributable to the synergies expected from capabilities in extraction and sample preparation and is not deductible for income tax purposes. We recorded $11.4 million for the fair value of acquired intangible assets, which consists of developed technology and customer relationships.

Invitae Collaboration

12 Months Ended

Dec. 31, 2022

Invitae Collaboration Arrangement [Abstract]

Invitae Collaboration

NOTE 3. INVITAE COLLABORATION

On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the “Amended and Restated Agreement”) with Invitae Corporation (“Invitae”). The Amended and Restated Agreement amended and restated the existing Development and Commercialization Agreement, effective as of January 12, 2021, as amended by Amendment No. 1 to Development and Commercialization Agreement, entered into on June 3, 2021, by and between us and Invitae (together, the “Original Agreement”). Unless otherwise agreed in writing or terminated in accordance with the Amended and Restated Agreement, the term of the Amended and Restated Agreement shall continue until June 30, 2028 (“Term”).

Pursuant to the Original Agreement, Invitae provided certain funding to us to develop products relating to production-scale high-throughput sequencing (“Program Products”). If Program Products were to become commercially available, Invitae had the right to purchase the Program Products at preferred pricing.

Under the Amended and Restated Agreement, we will continue to receive feedback, input and insight from Invitae in connection with the intended development of our new sequencing systems; however, such feedback will not be contractually required, and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems. Our development plans for such new sequencing systems will be at our discretion and pursuant to our own internal processes and programs. Invitae will not be contractually obligated to reimburse us for development costs under the Amended and Restated Agreement. There can be no assurances that the in-development sequencing systems will continue to be developed, be successfully developed or become available for commercial sale.

In consideration of the non-refundable payments received from Invitae pursuant to the Original Agreement of $23.5 million, we will provide Invitae with credits in connection with Invitae’s anticipated purchase of certain currently available and in-development sequencing systems (instruments and consumables). The credits will expire on June 30, 2025 (“Credit Expiration Date”). Subject to certain conditions, Invitae will also be entitled to most favored pricing for the Company’s Sequel IIe systems and certain in-development systems through the Term.

We and Invitae may terminate the Amended and Restated Agreement if the other party remains in material breach of the Amended and Restated Agreement following a cure period to remedy the material breach.

The Amended and Restated Agreement is deemed a contract modification and accounted for on a prospective basis in accordance with ASC Topic 606. We will recognize proportionate amounts of the transaction price, including payments made by Invitae to us pursuant to the Original Agreement, in revenue as the remaining performance obligations are satisfied, which is when Invitae places purchase orders for certain currently available and in-development sequencing platforms and the associated goods are delivered. Any remaining unused credits will be recognized when they expire.

During the year ended December 31, 2022, Invitae purchased certain currently available instruments, for which $3.7 million of revenue was recognized as product revenue on the Consolidated Statements of Operations and Comprehensive (Loss) Income under the terms of the Amended and Restated Agreement.

As of December 31, 2022, $21.4 million of deferred revenue, current, is recorded on the Consolidated Balance Sheet relating to all future performance obligations under the Amended and Restated Agreement.

Termination of Merger with Illumina

12 Months Ended

Dec. 31, 2022

Termination of Merger with Illumina [Abstract]

Termination of Merger with Illumina

NOTE 4. TERMINATION OF MERGER WITH ILLUMINA

On November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the “Illumina Merger Agreement”) with Illumina, Inc. (“Illumina”) and FC Ops Corp., a wholly owned subsidiary of Illumina (“Illumina Merger Sub”). On January 2, 2020, we, Illumina and Illumina Merger Sub, entered into an agreement to terminate the Merger Agreement (the “Termination Agreement”).

Continuation Advances from Illumina

As part of the Termination Agreement, Illumina paid us cash payments (“Continuation Advances”) totaling $52 million. Up to the full $52.0 million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March 31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $100 million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us.

Resulting from the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February 15, 2028, $52.0 million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded a non-operating expense in the Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2021.

Financial Instruments

12 Months Ended

Dec. 31, 2022

Financial Instruments [Abstract]

Financial Instruments

NOTE 5. FINANCIAL INSTRUMENTS

Fair Value of Financial Instruments

Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:

Level 1: quoted prices in active markets for identical assets or liabilities;

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.

We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.

The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December 31, 2022 and December 31, 2021, respectively:



	December 31, 2022								December 31, 2021
(in thousands)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Cash and cash equivalents:
Cash and money market funds	$	137,636	$	—	$	—	$	137,636	$	327,315	$	—	$	—	$	327,315
Commercial paper		—		166,453		—		166,453		—		133,185		—		133,185
U.S. government & agency securities		—		21,000		—		21,000		—		225		—		225
U.S. Treasury security		—		—		—		—		—		—		—		—
Total cash and cash equivalents		137,636		187,453		—		325,089		327,315		133,410		—		460,725
Investments:
Commercial paper		—		127,302		—		127,302		—		187,632		—		187,632
Corporate debt securities		—		49,491		—		49,491		—		8,968		—		8,968
U.S. government & agency securities		—		270,436		—		270,436		—		387,075		—		387,075
Total investments		—		447,229		—		447,229		—		583,675		—		583,675

Short-term restricted cash		300		—		—		300		500		—		—		500
Long-term restricted cash		2,922		—		—		2,922		4,592		—		—		4,592
Total assets measured at fair value	$	140,858	$	634,682	$	—	$	775,540	$	332,407	$	717,085	$	—	$	1,049,492

Liabilities
Contingent consideration	$	—	$	—	$	172,094	$	172,094	$	—	$	—	$	169,717	$	169,717
Total liabilities measured at fair value	$	—	$	—	$	172,094	$	172,094	$	—	$	—	$	169,717	$	169,717

We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value.

We estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate. The potential outcomes of milestone achievement dates are within the period from June 30, 2023 to June 30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which ranges from 10.1% to 10.5%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.

Changes in the estimated fair value of the contingent consideration liability for the year ended December 31, 2022 were as follows:



(in thousands)	Level 3
Beginning balance as of December 31, 2021	$	169,717
Change in estimated fair value		2,377
Ending balance as of December 31, 2022	$	172,094

Changes to the fair value are recorded as the Change in fair value of contingent consideration in the Consolidated Statement of Operations and Comprehensive (Loss) Income.

For the year ended December 31, 2022, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.

Cash, Cash Equivalents, Restricted Cash, and Investments

The following table summarizes our cash, cash equivalents, restricted cash, and investments:



	December 31, 2022
			Gross		Gross
	Amortized		unrealized		unrealized		Fair
(in thousands)	Cost		gains		losses		Value
Cash and cash equivalents:
Cash and money market funds	$	137,636	$	—	$	—	$	137,636
Commercial paper		166,514		—		(61)		166,453
U.S. government & agency securities		20,994		6		—		21,000
Total cash and cash equivalents		325,144		6		(61)		325,089
Investments:
Commercial paper		127,626		9		(333)		127,302
Corporate debt securities		49,998		—		(507)		49,491
U.S. government & agency securities		274,315		1		(3,880)		270,436
Total investments		451,939		10		(4,720)		447,229
Total cash, cash equivalents, and investments	$	777,083	$	16	$	(4,781)	$	772,318

Short-term restricted cash	$	300	$	—	$	—	$	300
Long-term restricted cash	$	2,922	$	—	$	—	$	2,922

	December 31, 2021
			Gross		Gross
	Amortized		unrealized		unrealized		Fair
(in thousands)	Cost		gains		losses		Value
Cash and cash equivalents:
Cash and money market funds	$	327,316	$	—	$	—	$	327,316
Commercial paper		133,190		—		(5)		133,185
U.S. government & agency securities		225		—		—		224
Total cash and cash equivalents		460,731		—		(5)		460,725
Investments:
Commercial paper		187,705		—		(73)		187,632
Corporate debt securities		8,964		9		(5)		8,968
U.S. government & agency securities		388,088		1		(1,014)		387,075
Total investments		584,757		10		(1,092)		583,675
Total cash, cash equivalents, and investments	$	1,045,488	$	10	$	(1,097)	$	1,044,400

Short-term restricted cash	$	500	$	—	$	—	$	500
Long-term restricted cash	$	4,592	$	—	$	—	$	4,592

The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December 31, 2022:



(in thousands)	Fair Value
Due in one year or less	$	564,752
Due after one year through 5 years		69,930
Total investments	$	634,682

Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.

Balance Sheet Components

12 Months Ended

Dec. 31, 2022

Balance Sheet Components [Abstract]

Balance Sheet Components

NOTE 6. BALANCE SHEET COMPONENTS

Inventory, Net

Inventory, net, consisted of the following components:



	December 31,
(in thousands)	2022		2021
Purchased materials	$	24,139	$	7,993
Work in process		14,062		8,611
Finished goods		12,180		7,995
Inventory, net	$	50,381	$	24,599

Property and Equipment, Net

Property and equipment, net, consisted of the following components:



	December 31,
(in thousands)	2022		2021
Laboratory equipment and machinery	$	38,998	$	31,534
Leasehold improvements		34,129		31,114
Computer equipment		18,438		15,059
Software		6,879		5,578
Furniture and fixtures		3,426		3,202
Construction in progress		4,698		2,303
Total		106,568		88,790
Less: Accumulated depreciation		(64,988)		(56,286)
Property and equipment, net	$	41,580	$	32,504

Construction in progress consists of capitalizable costs that have been incurred for the construction of long-lived assets, and is primarily comprised of amounts that will be classified as lab equipment.

Depreciation expense during the years ended December 31, 2022, 2021, and 2020 was $9.5 million, $7.2 million, and $6.4 million, respectively.

Goodwill and intangible Assets

Goodwill

As of December 31, 2022 and 2021, the goodwill balance was $410.0 million. Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2022, noting no impairment.

Acquired Intangible Assets

Intangible assets include acquired IPR&D of $400 million as a result of the Omniome acquisition in September 2021. As of December 31, 2022, the research and development project had not been completed or abandoned and, therefore, the IPR&D intangible asset is not currently subject to amortization. IPR&D is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for IPR&D impairment in the fourth quarter of 2022, noting no impairment.

In addition to IPR&D, we had the following acquired definite-lived intangible assets as of December 31, 2022 (in thousands, except years):



	Estimated	Gross				Net
	Useful Life	Carrying		Accumulated		Carrying
	(in years)	Amount		Amortization		Amount
Developed technology	15	$	11,179	$	(1,039)	$	10,140
Customer relationships	2		360		(255)		105
Total		$	11,539	$	(1,294)	$	10,245

Amortization expense of intangibles was $0.9 million and $0.4 million for the years ended December 31, 2022 and 2021, respectively. We had no amortization expense of intangibles for the year ended December 31, 2020.

The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):



2023	$	853
2024		745
2025		745
2026		745
2027		746
2028 and thereafter		6,411
Total	$	10,245

Accrued Expenses

Accrued expenses consisted of the following components:



	December 31,
(in thousands)	2022		2021
Salaries and benefits	$	17,432	$	25,282
Accrued interest payable		5,100		5,100
Accrued purchase commitments		3,705		—
Accrued product development costs		2,326		1,936
Accrued professional services and legal fees		1,005		1,640
Inventory accrual		332		108
Warranty accrual		1,651		594
Other		1,045		1,601
Accrued expenses	$	32,596	$	36,261

Product Warranties

We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below.

Changes in the reserve for product warranties were as follows:



	Years Ended December 31,
(in thousands)	2022		2021
Balance at beginning of period	$	594	$	161
Additions charged to cost of product revenue		3,199		2,120
Repairs and replacements		(2,142)		(1,687)
Balance at end of period	$	1,651	$	594

Deferred Revenue

As of December 31, 2022, we had a total of $32.3 million of deferred revenue, $30.5 million of which was recorded as deferred revenue, current and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae as described in Note 3. Invitae Collaboration. The deferred revenue, non-current balance of $1.8 million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next 6 years. Revenue recorded in the year ended December 31, 2022 includes $13.0 million of previously deferred revenue that was included in deferred revenue, current as of December 31, 2021.

Term Loans

In connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome’s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24^th month and before the 43^rd month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest.

As of December 31, 2022, the carrying value of term loans outstanding was $2.3 million. The related long-term portion of $0.5 million was recorded as part of other liabilities, non-current and the short-term portion of $1.8 million was recorded as part of other liabilities, current on the Consolidated Balance Sheet. The interest expense was $0.6 million for the year ended December 31, 2022, which was included as part of interest expense in the Consolidated Statement of Operations and Comprehensive (Loss) Income.
‎

As of December 31, 2022, the future principal payments remaining on term loans was the following:



(in thousands)
2023	$	1,842
2024		490
Total	$	2,332

Other Liabilities, Current

Other liabilities, current, consisted of the following components:


	December 31,
(in thousands)	2022		2021
Accrued Employee Stock Purchase Plan	$	3,638	$	3,598
Short-term loan		1,842		1,608
Other		1,753		553
Other liabilities, current	$	7,233	$	5,759

Convertible Senior Notes

12 Months Ended

Dec. 31, 2022

Convertible Senior Notes [Abstract]

Convertible Senior Notes

NOTE 7. CONVERTIBLE SENIOR NOTES

On February 9, 2021, we entered into an investment agreement (the “Investment Agreement”) with SB Northstar LP (the “Purchaser”), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $900 million in aggregate principal amount of our 1.50% Convertible Senior Notes (the “Notes”). The Notes were issued on February 16, 2021.

The Notes are governed by an indenture (the “Indenture”) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of 1.50% per annum. Interest on the Notes is payable semi-annually in arrears on February 15 and August 15 and commenced on August 15, 2021. The Notes will mature on February 15, 2028, subject to earlier conversion, redemption, or repurchase.

The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $43.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash.

On or after February 20, 2026, the Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.

With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges (a “Fundamental Change”), the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.

The Indenture includes customary “events of default,” which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.

To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the Notes at a rate equal to (i) 0.25% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided for in the Indenture.

The Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the Notes were not issued at a premium; therefore, the Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.

The requirement to repurchase the Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 – Derivatives and Hedging. However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.

The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.

We incurred issuance costs related to the Notes of approximately $4.5 million, which were recorded as debt issuance cost and are presented as a reduction to the Notes on our Consolidated Balance Sheets and are amortized to interest expense using the effective interest method over the term of the Notes, resulting in an effective interest rate of 1.6%.

As of December 31, 2022, the net carrying amount of the liability for the Notes is recorded as convertible senior notes, net in the Consolidated Balance Sheets as follows (in thousands):



Principal amount	$	900,000
Unamortized debt issuance costs		(3,317)
Net carrying amount	$	896,683

Interest expense for the Notes was as follows for the years ended December 31, 2022, 2021, and 2020:



	Years Ended December 31,
(in thousands)	2022		2021		2020
Contractual interest expense	$	13,500	$	11,812	$	-
Amortization of debt issuance costs		617		532		-
Total interest expense	$	14,117	$	12,344	$	-

As of December 31, 2022, the estimated fair value (Level 2) of the Notes was $604.8 million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies [Abstract]

Commitments and Contingencies

NOTE 8. COMMITMENTS AND CONTINGENCIES

Leases

We record operating lease right-of-use assets and liabilities on our Consolidated Balance Sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $18.1 million in right-of-use assets and liabilities on our Consolidated Balance Sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.

We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.

‎

As of December 31, 2022, the maturities of our operating lease liabilities were as follows:



(in thousands)
2023	$	11,955
2024		12,018
2025		12,279
2026		12,392
2027		9,930
Thereafter		—
Total undiscounted operating lease payments		58,574
Less: imputed interest		(8,618)
Present value of operating lease liabilities	$	49,956

Balance Sheet Classification
Operating lease liabilities, current	$	8,886
Operating lease liabilities, non-current		41,070
Total operating lease liabilities	$	49,956

We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was 6.7%. The weighted-average remaining lease term for our operating leases as of December 31, 2022 was 4.7 years.

Cash Flows

Cash paid for amounts included in the present value of operating lease liabilities was $11.2 million and $8.2 million for the years ended December 31, 2022 and 2021, respectively, and were included in operating cash flow.

Operating Lease Costs

Operating lease costs were $10.5 million and $7.2 million for the years ended December 31, 2022 and 2021, respectively.

Contingencies

We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.

Please see subsection titled Legal Proceedings, in Part I, Item 3 of this Annual Report on Form 10-K.

Indemnification

Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of December 31, 2022.

Purchase Commitments

In the normal course of business, we enter into agreements to purchase goods or services or license intellectual property, certain of which are not cancelable without penalty. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to ongoing minimum royalty payments, some of which are subject to adjustment, may be terminated under certain circumstances.

Our purchase orders and contractual obligations are approximately $145.7 million as of December 31, 2022, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.

We recognized a loss on purchase commitment of $3.7 million for the year ended December 31, 2022, which was recorded as part of accrued expenses on the Consolidated Balance Sheet and is included in the aforementioned purchase orders and contractual obligations amount. The purchase commitment loss is based on an estimate of future excess inventory related to a supply agreement with a third-party vendor, for which we do not expect to have related sales.

We have a long-term supply agreement, which was amended in October 2022 (the “Supply Agreement”), for the purchase of certain products with a semiconductor manufacturer (“Supplier”). The Supply Agreement provides for minimum purchase commitments through 2026 on our part in exchange for guaranteed capacity at Supplier. We are responsible for providing certain materials to allow our Supplier to perform its obligations under the contract.

We paid our Supplier a deposit of $9.0 million in November 2022 and will pay an additional deposit of $6.0 million in 2023, for a total of $15.0 million (the “Deposit”). The Deposit is fully refundable to us, in accordance with the Supply Agreement, if we meet the minimum volume purchase commitment for the applicable year. As of December 31, 2022, $9.0 million related to the Deposit was included in other long-term assets in the Consolidated Balance Sheets, as we believe it is probable the minimum volume purchase commitment level will be achieved.

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Taxes [Abstract]

Income Taxes

NOTE 9. INCOME TAXES

We are subject to income taxes in the United States and certain states in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities, and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.

We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.

We account for Global Intangible Low-taxed Income as a period cost.

During the years ended December 31, 2022, 2021, and 2020 (loss) income before taxes from U.S. operations were ($315.7) million, ($275.4) million, and $28.9 million, respectively, and income before taxes from foreign operations was $1.8 million, $0.8 million, and $0.6 million, respectively.

Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax income or loss as follows:



	Years ended December 31,
	2022		2021		2020
Statutory tax rate	21.0	%	21.0	%	21.0	%
State tax rate, net of federal benefit	4.4		5.5		(8.3)
Change in valuation allowance	(25.1)		(4.9)		6.3
Tax credits	2.2		2.5		(3.6)
Share-based compensation	(2.2)		10.9		(15.2)
Merger Expenses	-		(0.9)		-
Other	(0.4)		(0.1)		(0.2)
Total	(0.1)	%	34.0	%	0.0	%

Deferred income taxes reflect the net tax effects of loss and credit carry forwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):



	December 31,
	2022		2021
Deferred tax assets:
Net operating loss carryforwards	$	400,629	$	378,035
Research and development credits		71,526		60,672
Capitalized research and experimental expenses		34,863		—
Accruals and reserves		18,417		10,822
Share-based compensation		17,117		12,838
Operating lease liability		11,537		13,105
Total deferred tax assets		554,089		475,472
Less: Valuation allowance		(445,574)		(366,940)
Total deferred tax assets:		108,515		108,532
Intangibles		(98,931)		(97,345)
Fixed assets		(1,262)		(1,523)
Operating lease right-of-use assets		(9,157)		(10,502)
Total deferred tax liabilities		(109,350)		(109,370)
Net deferred tax assets	$	(835)	$	(838)

At December 31, 2022, we maintained a full valuation allowance against all of our deferred tax assets that totaled $445.6 million, including net operating loss carryforwards and research and development credits of $400.6 million and $71.5 million, respectively.

A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our Consolidated Statements of Operations and Comprehensive (Loss) Income for the year ended December 31, 2022.

For the year ended December 31, 2022, our valuation allowance increased to $445.6 million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. For the year ended December 31, 2021, our valuation allowance increased to $366.9 million, primarily because of an increase in our net operating losses, credits, and acquisition of deferred tax assets that were fully offset by a valuation allowance.

As of December 31, 2022, we had a net operating loss carryforward for federal income tax purposes of approximately $1,573.8 million, of which $774.9 million will begin to expire in 2024 if not utilized. We had a total state net operating loss carryforward of approximately $1,071.8 million, which are subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the “change of ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization.

We have federal credits of approximately $47.2 million, which will begin to expire in 2024 if not utilized and state research credits of approximately $42.6 million, which have no expiration date. These tax credits are subject to the same limitations discussed above.

As of December 31, 2022, our total unrecognized tax benefit was $10.4 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands):



Balance as of December 31, 2019	$	21,979
Decrease in balance related to tax positions taken in prior year		(17,255)
Increase in balance related to tax positions taken during current year		1,230
Balance as of December 31, 2020		5,954
Increase in balance related to tax positions taken in prior year		189
Increase in balance related to tax positions taken during current year		2,192
Balance as of December 31, 2021		8,335
Decrease in balance related to tax positions taken in prior year		(10)
Increase in balance related to tax positions taken during current year		2,085
Balance as of December 31, 2022	$	10,410

Our practice is to recognize interest and penalties related to income tax matters in income tax expense. As of both December 31, 2022 and 2021, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December 31, 2019 to present and December 31, 2018 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2022

Stockholders' Equity [Abstract]

Stockholders' Equity

NOTE 10. STOCKHOLDERS’ EQUITY

Preferred Stock

Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December 31, 2022 and 2021, there were no shares of preferred stock issued or outstanding.

Common Stock

Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.

Underwritten Public Equity Offerings

In August 2020, we entered into an underwriting agreement, relating to the public offering of 19,430,000 shares of our common stock, $0.001 par value per share, at a price to the public of $4.47 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2,914,500 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters’ option, closed in August 2020. In total, we sold 22.3 million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9 million, excluding approximately $0.3 million of offering expenses.

In November 2020, we entered into an underwriting agreement, relating to the public offering of 6,096,112 shares of our common stock, $0.001 par value per share, at a price to the public of $14.25 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 914,416 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters’ option, closed in November 2020. In total, we sold 7.0 million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9 million, excluding approximately $0.3 million of offering expenses.

In total, for the year ended December 31, 2020, we issued 29.4 million shares of our common stock through our two underwritten public offerings with an average offering price of $6.40. The total net proceeds to us from the two offerings, after deducting the underwriting commission and offering expenses, were approximately $187.2 million.

Private Placement of Common Stock

On July 19, 2021, in connection with the Omniome acquisition, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of 11,214,953 shares of common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300 million. The transaction closed on September 20, 2021. We registered the private placement shares for resale following the closing of the merger.

Equity Plans

The 2020 Equity Incentive Plan (the “2020 Plan”), the 2020 Inducement Equity Incentive Plan (the “Inducement Plan”), and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the “Omniome Plan”) allow for the issuance of stock options, restricted units and awards, and performance-based awards.

On August 4, 2020, stockholders approved the 2020 Plan and reserved 11,000,000 shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.

On December 2, 2020, the Board of Directors (the “Board”) adopted the Inducement Plan and reserved 2,500,000 shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 18, 2021 and November 22, 2021, the Board amended the Inducement Plan to reserve an additional 750,000 and 360,000 shares, respectively.

On September 20, 2021, in connection with the acquisition of Omniome, we adopted the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the “Omniome Plan”). Under the Omniome Merger Agreement, each unvested option to purchase Omniome common stock, granted under the Omniome Plan held by employees continuing with us, was assumed by PacBio and converted into an option to purchase shares of our common stock. The terms and conditions of the converted options are substantially the same (including vesting and exercisability), except that (A) the assumed options cover shares of PacBio’s common stock; (B) the number of shares of our common stock subject to the assumed option is equal to the product of (i) the number of shares of Omniome common stock subject to the corresponding unvested option, multiplied by (ii) the exchange ratio (as defined below), with any resulting fractional share rounded down to the nearest whole share; and (C) the exercise price per share of the assumed options is equal to the quotient of (i) the exercise price per share of the corresponding unvested option to purchase shares of Omniome common stock, divided by (ii) the exchange ratio (as defined below), with any resulting fractional cent rounded up to the nearest whole cent. The exchange ratio was equal to 0.259204639. We reserved 2,494,128 shares of our common stock for issuance pursuant to equity awards under the Omniome Plan.

On May 25, 2022, stockholders approved an amendment to the 2020 Plan and we reserved an additional 18,000,000 shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.

As of December 31, 2022, we had 18.9 million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan.

Stock Options

Time-based stock options

The following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December 31, 2022 (in thousands, except per share amounts):




	Number	Weighted-average
	of shares	exercise price
Outstanding at December 31, 2021	12,159	$	11.38
Granted	5,211	$	10.34
Exercised	(1,052)	$	3.25
Canceled	(1,603)	$	19.66
Expired	(97)	$	24.26
Outstanding at December 31, 2022	14,618	$	10.60

Performance-based stock options

The following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December 31, 2022 (in thousands, except per share amounts):



	Number	Weighted-average
	of shares	exercise price
Outstanding at December 31, 2021	304	$	4.71
Granted	—	$	—
Exercised	—	$	—
Canceled	(46)	$	4.71
Outstanding at December 31, 2022	258	$	4.71

The aggregate intrinsic value of outstanding options represents the total pre-tax intrinsic value (i.e. the difference between $8.18, our closing stock price on the last trading day of our fourth quarter of 2022 and the option exercise price multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2022. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock.

The aggregate intrinsic value of the outstanding options presented in the table above as of December 31, 2022, totaled $24.7 million, and had a weighted-average remaining contractual life of 6.7 years.

The vested and exercisable options as of December 31, 2022, totaled 9,408,063 shares, had an aggregate intrinsic value of $22.7 million, a weighted-average exercise price per share of $8.45, and a weighted-average remaining contractual life of 5.4 years.

The vested and expected to vest options as of December 31, 2022, totaled 14,436,695 shares, had an aggregate intrinsic value of $24.6 million, a weighted-average exercise price per share of $10.61, and a weighted-average remaining contractual life of 6.5 years.

The total intrinsic value of stock options exercised during the years ended December 31, 2022, 2021, and 2020 was $5.0 million, $146.1 million, and $63.1 million, respectively.

The total intrinsic value of options exercised represents the difference between our closing stock price on the exercise date and the option exercise price, multiplied by the number of in-the-money options exercised.

The weighted-average grant-date fair value of all options granted was $5.93 in 2022, $18.36 in 2021, and $4.14 in 2020, each determined by the Black-Scholes option valuation method.

Restricted Stock Units

Each Restricted Stock Unit (RSU) represents one equivalent share of our common stock to be issued after satisfying the applicable continued service-based vesting criteria over a specified period. These RSUs are time-based and vest over four years at a rate of 25% annually. The fair value for these RSUs is based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. RSUs that are expected to vest are net of estimated future forfeitures.

The following table summarizes the RSU activity for the year ended December 31, 2022 (in thousands, except per share amounts):



		Weighted-average
	Number	grant date
	of shares	fair value
RSUs outstanding at December 31, 2021	7,392	$	19.78
RSUs granted	5,389	$	10.15
RSUs released	(2,582)	$	15.19
RSUs forfeited	(1,664)	$	19.42
Unvested RSUs outstanding at December 31, 2022	8,535	$	15.16

The total fair value of shares vested related to RSUs during the years ended December 31, 2022, 2021, and 2020 was $39.2 million, $9.2 million, and $6.3 million, respectively.

The weighted-average grant-date fair value of all RSUs granted was $10.15 in 2022, $35.33 in 2021, and $5.18 in 2020.

Employee Stock Purchase Plan

As of December 31, 2022, a total of 25.5 million shares of our common stock have been reserved for issuance under our 2010 Employee Stock Purchase Plan (the “ESPP”). The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of four purchase periods, each purchase period being approximately six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. Each offering period will generally end and the shares will be purchased twice yearly on March 1 and September 1. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will be terminated and a new offering period will come into place. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lessor of 2% of the common shares then outstanding, 4,000,000 shares, or an amount determined by the ESPP’s administrator.

Pursuant to the terms of the then-in-process Merger Agreement with Illumina, offerings under our 2010 ESPP were suspended after the completion of the purchase period ended March 1, 2019. After the merger with Illumina was terminated in January 2020, we began offerings under the ESPP again starting with the offering period beginning March 1, 2020.

For the years ended December 31, 2022, 2021, and 2020, 1,878,168 shares, 1,913,968 shares, and 834,677 shares of common stock were purchased under the ESPP, respectively. As of December 31, 2022, 9,932,505 shares of our common stock remain available for issuance under our ESPP.

Share-based Compensation

Total share-based compensation expense consists of the following (in thousands):



	Years Ended December 31,
	2022		2021		2020
Cost of revenue	$	4,802	$	6,126	$	2,236
Research and development		30,676		20,275		7,061
Sales, general and administrative		43,135		35,403		8,236
Merger-related expenses - stock-settled		—		6,349		—
Merger-related expenses - milestone		—		5,202		—
Share-based compensation		78,613		73,355		17,533
Merger-related expenses - cash-settled		—		7,373		—
Total share-based compensation expense	$	78,613	$	80,728	$	17,533

As of December 31, 2022 and 2021, $0.7 million and $0.9 million of share-based compensation cost was capitalized in inventory, net, on our consolidated balance sheets, respectively.

The tax benefit of share-based compensation expense was immaterial for the years ended December 31, 2022, 2021, and 2020.

Determining Fair Value

We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.

Expected Term – The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.

Expected Volatility – The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.

Expected Dividend – We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.

Risk-Free Interest Rate – The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.

Stock Options

We estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards.

When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets.

The fair value of employee stock options was estimated using the following weighted-average assumptions:



	Years Ended December 31,
	2022		2021		2020
Expected term in years		4.6		2.1 - 4.6		5.0
Expected volatility		70% - 76%		67% - 80%		70.7%
Risk-free interest rate		0.41% – 3.66%		0.05% – 1.10%		0.3%
Dividend yield		—		—		—
Weighted-average grant date fair value per share	$	5.93	$	15.53	$	7.20

Cash received from option exercises for the years ended December 31, 2022, 2021, and 2020 was $3.4 million, $25.4 million and $43.9 million, respectively.

ESPP

We estimate the fair value of shares to be issued under the ESPP using the Black-Scholes option pricing model. The fair value of shares to be issued under the ESPP was estimated using the following assumptions:



	Years Ended December 31,
	2022		2021		2020
Expected term in years		0.5 - 2.0		0.5 - 2.0		0.5 - 2.0
Expected volatility		70% - 97%		67% - 68%		57% - 71%
Risk-free interest rate		0.60% - 3.51%		0.1% - 0.2%		0.1%-1.0%
Dividend yield		—		—		—
Weighted-average grant date fair value per share	$	4.28	$	25.07	$	1.87

Cash received through the ESPP for the years ended December 31, 2022, 2021, and 2020 was $7.8 million, $6.4 million, and $2.4 million, respectively.

As of December 31, 2022, $125.1 million of total unrecognized compensation expense related to stock options, restricted stock, and ESPP shares was expected to be recognized over a weighted-average period of 2.4 years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Net (Loss) Income Per Share

12 Months Ended

Dec. 31, 2022

Net (Loss) Income Per Share [Abstract]

Net (Loss) Income Per Share

NOTE 11. NET (LOSS) INCOME PER SHARE

Basic net (loss) income per share and diluted net (loss) income per share are presented for the three years presented.

The following table presents the calculation of weighted-average shares of common stock used in the computations of basic and diluted net (loss) income per share amounts presented in the accompanying consolidated statements of operations and comprehensive (loss) income (in thousands, except per share amounts):



	Years Ended December 31,
	2022		2021		2020
Numerator:
Net (loss) income	$	(314,248)	$	(181,223)	$	29,403

Denominator:
Basic
Weighted-average shares used in computing basic net (loss) income per share		224,550		204,136		165,187
Basic net (loss) income per share	$	(1.40)	$	(0.89)	$	0.18
Diluted
Weighted-average shares used in computing basic net (loss) income per share		224,550		204,136		165,187
Add: weighted-average stock options		—		—		6,092
Add: weighted-average restricted stock units		—		—		2,324
Add: weighted-average common stock issuable pursuant to our ESPP		—		—		1,367
Weighted-average shares used in computing diluted net (loss) income per share		224,550		204,136		174,970
Diluted net (loss) income per share	$	(1.40)	$	(0.89)	$	0.17

The following shares issuable upon conversion of convertible senior notes, options outstanding, time-based RSUs, performance-based RSUs, and ESPP shares to purchase common stock were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:



	Years Ended December 31,
(in thousands)	2022	2021	2020
Shares issuable upon conversion of convertible senior notes	20,690	20,690	—
Options to purchase common stock	14,876	12,463	4,908
RSUs with time-based vesting	8,535	7,392	100
RSUs with performance-based vesting	—	—	94
ESPP shares	3,880	1,564	2,890

As described in Note 2. Business Acquisitions, the contingently issuable shares would be due upon the achievement of a milestone. See Note 10. Stockholders’ Equity for detailed information on RSUs with time-based vesting and RSUs with performance-based vesting.

Segment And Geographic Information

12 Months Ended

Dec. 31, 2022

Segment And Geographic Information [Abstract]

Segment And Geographic Information

NOTE 12. SEGMENT AND GEOGRAPHIC INFORMATION

We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.

A summary of our revenue by geographic location is as follows:



	Years Ended December 31,
(in thousands)	2022		2021		2020
Americas	$	69,561	$	64,521	$	37,277
Europe, Middle East, and Africa		22,598		30,271		19,065
Asia-Pacific		36,145		35,721		22,551
Total	$	128,304	$	130,513	$	78,893

A summary of our revenue by category is as follows:



	Years Ended December 31,
(in thousands)	2022		2021		2020
Instrument revenue	$	48,719	$	61,324	$	34,282
Consumable revenue		59,980		52,181		31,142
Product revenue		108,699		113,505		65,424
Service and other revenue		19,605		17,008		13,469
Total revenue	$	128,304	$	130,513	$	78,893

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	NOTE 13. SUBSEQUENT EVENTSOn January 27, 2023, the Company issued and sold an aggregate of 20,125,000 shares of the Company’s common stock at a purchase price of $10.00 per share pursuant to an automatic shelf registration statement filed on Form S-3 (File No. 333-249999) with the Securities and Exchange Commission, resulting in aggregate gross proceeds of approximately $201.3 million.

Organization and Significant Accounting Policies (Policy)

12 Months Ended

Dec. 31, 2022

Organization and Significant Accounting Policies [Abstract]

Basis of Presentation and Consolidation

Use of Estimates

Functional Currency

Cash, Cash Equivalents, Restricted Cash, and Investments

Restricted cash includes cash that is not readily available for use in the Company’s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.

Concentration and Other Risks

For the years ended December 31, 2022, 2021, and 2020, one customer accounted for approximately 12%, 13%, and 14% of our total revenue, respectively.

Inventory, Net

Property and Equipment, Net

Estimated useful lives of the major classes of property and equipment are as follows:



		Estimated Useful Lives
Leasehold improvements		3 to 10 years
Lab equipment		3 to 5 years
Computer equipment		3 to 5 years
Computer software		3 years
Furniture and fixtures		3 to 5 years

Operating Leases

Business Combinations

Goodwill, Intangible Assets, and Other Long-Lived Assets

Revenue Recognition

Cost of Revenue

Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.

Research and Development

Credit Losses

Trade accounts receivable

Available-for-sale debt securities

Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of the COVID-19 pandemic, or other customer-specific factors.

Income Taxes

Share-based Compensation

Other Comprehensive (Loss) Income

Other comprehensive (loss) income is comprised of unrealized (losses) gains on our investment securities.

Shipping and Handling

Costs related to shipping and handling are included in cost of revenues for all periods presented.

Earnings Per Share

Earnings per Share

Recently Adopted Accounting Standards

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

There are no accounting standards updates (“ASUs”) that have been recently adopted and are applicable to our consolidated financial statements.

Accounting Pronouncements Pending Adoption

Business Acquisition (Tables)

12 Months Ended

Dec. 31, 2022

Omniome, Inc [Member]

Business Acquisition [Line Items]

Total Consideration Transferred For Acquisition


Total cash paid	$	315,703
Fair value of share consideration		249,435
Fair value of contingent consideration		168,574
Less: Share-based compensation expense excluded from consideration transferred		(18,923)
Total consideration transferred	$	714,789

Major Classes Of Assets And Liabilities Allocated To Total Fair Value Of The Consideration Transferred


Cash and cash equivalents	$	15,338
Property and equipment, net		6,123
Operating lease right-of-use assets, net		18,095
In-process research and development ("IPR&D")		400,000
Goodwill		390,665
Other assets		3,203
Deferred income tax liability		(91,814)
Liabilities assumed		(26,821)
Total consideration transferred	$	714,789

Unaudited Pro Forma Financial Information


	Years Ended December 31,
(in thousands, except per share amounts)	2021		2020
Pro forma total revenue	$	130,513	$	78,893
Pro forma net (loss) income	$	(278,451)	$	17,510
Pro forma net (loss) income per share - basic and diluted	$	(1.27)	$	0.09

Circulomics, Inc [Member]

Business Acquisition [Line Items]

Major Classes Of Assets And Liabilities Allocated To Total Fair Value Of The Consideration Transferred


Cash and cash equivalents	$	987
Property and equipment, net		214
Intangible assets		11,360
Goodwill		19,309
Other assets		467
Deferred income tax liability		(2,672)
Liabilities assumed		(118)
Total consideration transferred	$	29,547

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2022

Financial Instruments [Abstract]

Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis



	December 31, 2022								December 31, 2021
(in thousands)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Cash and cash equivalents:
Cash and money market funds	$	137,636	$	—	$	—	$	137,636	$	327,315	$	—	$	—	$	327,315
Commercial paper		—		166,453		—		166,453		—		133,185		—		133,185
U.S. government & agency securities		—		21,000		—		21,000		—		225		—		225
U.S. Treasury security		—		—		—		—		—		—		—		—
Total cash and cash equivalents		137,636		187,453		—		325,089		327,315		133,410		—		460,725
Investments:
Commercial paper		—		127,302		—		127,302		—		187,632		—		187,632
Corporate debt securities		—		49,491		—		49,491		—		8,968		—		8,968
U.S. government & agency securities		—		270,436		—		270,436		—		387,075		—		387,075
Total investments		—		447,229		—		447,229		—		583,675		—		583,675

Short-term restricted cash		300		—		—		300		500		—		—		500
Long-term restricted cash		2,922		—		—		2,922		4,592		—		—		4,592
Total assets measured at fair value	$	140,858	$	634,682	$	—	$	775,540	$	332,407	$	717,085	$	—	$	1,049,492

Liabilities
Contingent consideration	$	—	$	—	$	172,094	$	172,094	$	—	$	—	$	169,717	$	169,717
Total liabilities measured at fair value	$	—	$	—	$	172,094	$	172,094	$	—	$	—	$	169,717	$	169,717

Changes in the estimated fair value of contingent consideration liabilities



(in thousands)	Level 3
Beginning balance as of December 31, 2021	$	169,717
Change in estimated fair value		2,377
Ending balance as of December 31, 2022	$	172,094

Summary of Cash, Cash Equivalents and Investments



	December 31, 2022
			Gross		Gross
	Amortized		unrealized		unrealized		Fair
(in thousands)	Cost		gains		losses		Value
Cash and cash equivalents:
Cash and money market funds	$	137,636	$	—	$	—	$	137,636
Commercial paper		166,514		—		(61)		166,453
U.S. government & agency securities		20,994		6		—		21,000
Total cash and cash equivalents		325,144		6		(61)		325,089
Investments:
Commercial paper		127,626		9		(333)		127,302
Corporate debt securities		49,998		—		(507)		49,491
U.S. government & agency securities		274,315		1		(3,880)		270,436
Total investments		451,939		10		(4,720)		447,229
Total cash, cash equivalents, and investments	$	777,083	$	16	$	(4,781)	$	772,318

Short-term restricted cash	$	300	$	—	$	—	$	300
Long-term restricted cash	$	2,922	$	—	$	—	$	2,922

	December 31, 2021
			Gross		Gross
	Amortized		unrealized		unrealized		Fair
(in thousands)	Cost		gains		losses		Value
Cash and cash equivalents:
Cash and money market funds	$	327,316	$	—	$	—	$	327,316
Commercial paper		133,190		—		(5)		133,185
U.S. government & agency securities		225		—		—		224
Total cash and cash equivalents		460,731		—		(5)		460,725
Investments:
Commercial paper		187,705		—		(73)		187,632
Corporate debt securities		8,964		9		(5)		8,968
U.S. government & agency securities		388,088		1		(1,014)		387,075
Total investments		584,757		10		(1,092)		583,675
Total cash, cash equivalents, and investments	$	1,045,488	$	10	$	(1,097)	$	1,044,400

Short-term restricted cash	$	500	$	—	$	—	$	500
Long-term restricted cash	$	4,592	$	—	$	—	$	4,592

Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments



(in thousands)	Fair Value
Due in one year or less	$	564,752
Due after one year through 5 years		69,930
Total investments	$	634,682

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Balance Sheet Components (Tables)

12 Months Ended

Dec. 31, 2022

Balance Sheet Components [Abstract]

Components of Inventory



	December 31,
(in thousands)	2022		2021
Purchased materials	$	24,139	$	7,993
Work in process		14,062		8,611
Finished goods		12,180		7,995
Inventory, net	$	50,381	$	24,599

Components of Property and Equipment, Net



	December 31,
(in thousands)	2022		2021
Laboratory equipment and machinery	$	38,998	$	31,534
Leasehold improvements		34,129		31,114
Computer equipment		18,438		15,059
Software		6,879		5,578
Furniture and fixtures		3,426		3,202
Construction in progress		4,698		2,303
Total		106,568		88,790
Less: Accumulated depreciation		(64,988)		(56,286)
Property and equipment, net	$	41,580	$	32,504

Definite-lived intangible assets from business acquisitions



	Estimated	Gross				Net
	Useful Life	Carrying		Accumulated		Carrying
	(in years)	Amount		Amortization		Amount
Developed technology	15	$	11,179	$	(1,039)	$	10,140
Customer relationships	2		360		(255)		105
Total		$	11,539	$	(1,294)	$	10,245

Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives



2023	$	853
2024		745
2025		745
2026		745
2027		746
2028 and thereafter		6,411
Total	$	10,245

Schedule of Accrued Expenses



	December 31,
(in thousands)	2022		2021
Salaries and benefits	$	17,432	$	25,282
Accrued interest payable		5,100		5,100
Accrued purchase commitments		3,705		—
Accrued product development costs		2,326		1,936
Accrued professional services and legal fees		1,005		1,640
Inventory accrual		332		108
Warranty accrual		1,651		594
Other		1,045		1,601
Accrued expenses	$	32,596	$	36,261

Changes in Reserve for Product Warranties



	Years Ended December 31,
(in thousands)	2022		2021
Balance at beginning of period	$	594	$	161
Additions charged to cost of product revenue		3,199		2,120
Repairs and replacements		(2,142)		(1,687)
Balance at end of period	$	1,651	$	594

Future Principal Payments , Fiscal Year Maturity



(in thousands)
2023	$	1,842
2024		490
Total	$	2,332

Schedule of Other Liabilities, Current


	December 31,
(in thousands)	2022		2021
Accrued Employee Stock Purchase Plan	$	3,638	$	3,598
Short-term loan		1,842		1,608
Other		1,753		553
Other liabilities, current	$	7,233	$	5,759

Convertible Senior Notes (Tables)

12 Months Ended

Dec. 31, 2022

Convertible Senior Notes [Abstract]

Schedule of Net Carrying Amount



Principal amount	$	900,000
Unamortized debt issuance costs		(3,317)
Net carrying amount	$	896,683

Schedule of Interest Expense



	Years Ended December 31,
(in thousands)	2022		2021		2020
Contractual interest expense	$	13,500	$	11,812	$	-
Amortization of debt issuance costs		617		532		-
Total interest expense	$	14,117	$	12,344	$	-

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies [Abstract]

Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases



(in thousands)
2023	$	11,955
2024		12,018
2025		12,279
2026		12,392
2027		9,930
Thereafter		—
Total undiscounted operating lease payments		58,574
Less: imputed interest		(8,618)
Present value of operating lease liabilities	$	49,956

Balance Sheet Classification
Operating lease liabilities, current	$	8,886
Operating lease liabilities, non-current		41,070
Total operating lease liabilities	$	49,956

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Taxes [Abstract]

Reconciliation of Federal Income Tax Rate



	Years ended December 31,
	2022		2021		2020
Statutory tax rate	21.0	%	21.0	%	21.0	%
State tax rate, net of federal benefit	4.4		5.5		(8.3)
Change in valuation allowance	(25.1)		(4.9)		6.3
Tax credits	2.2		2.5		(3.6)
Share-based compensation	(2.2)		10.9		(15.2)
Merger Expenses	-		(0.9)		-
Other	(0.4)		(0.1)		(0.2)
Total	(0.1)	%	34.0	%	0.0	%

Reconciliation of Deferred Tax Assets and Liabilities



	December 31,
	2022		2021
Deferred tax assets:
Net operating loss carryforwards	$	400,629	$	378,035
Research and development credits		71,526		60,672
Capitalized research and experimental expenses		34,863		—
Accruals and reserves		18,417		10,822
Share-based compensation		17,117		12,838
Operating lease liability		11,537		13,105
Total deferred tax assets		554,089		475,472
Less: Valuation allowance		(445,574)		(366,940)
Total deferred tax assets:		108,515		108,532
Intangibles		(98,931)		(97,345)
Fixed assets		(1,262)		(1,523)
Operating lease right-of-use assets		(9,157)		(10,502)
Total deferred tax liabilities		(109,350)		(109,370)
Net deferred tax assets	$	(835)	$	(838)

Reconciliation of Unrecognized Tax Benefit Accounts



Balance as of December 31, 2019	$	21,979
Decrease in balance related to tax positions taken in prior year		(17,255)
Increase in balance related to tax positions taken during current year		1,230
Balance as of December 31, 2020		5,954
Increase in balance related to tax positions taken in prior year		189
Increase in balance related to tax positions taken during current year		2,192
Balance as of December 31, 2021		8,335
Decrease in balance related to tax positions taken in prior year		(10)
Increase in balance related to tax positions taken during current year		2,085
Balance as of December 31, 2022	$	10,410

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2022

Summary of Time-Based RSUs Activity



		Weighted-average
	Number	grant date
	of shares	fair value
RSUs outstanding at December 31, 2021	7,392	$	19.78
RSUs granted	5,389	$	10.15
RSUs released	(2,582)	$	15.19
RSUs forfeited	(1,664)	$	19.42
Unvested RSUs outstanding at December 31, 2022	8,535	$	15.16

Schedule of Stock-Based Compensation Expense



	Years Ended December 31,
	2022		2021		2020
Cost of revenue	$	4,802	$	6,126	$	2,236
Research and development		30,676		20,275		7,061
Sales, general and administrative		43,135		35,403		8,236
Merger-related expenses - stock-settled		—		6,349		—
Merger-related expenses - milestone		—		5,202		—
Share-based compensation		78,613		73,355		17,533
Merger-related expenses - cash-settled		—		7,373		—
Total share-based compensation expense	$	78,613	$	80,728	$	17,533

Schedule of Fair Value of Employee Stock Options



	Years Ended December 31,
	2022		2021		2020
Expected term in years		4.6		2.1 - 4.6		5.0
Expected volatility		70% - 76%		67% - 80%		70.7%
Risk-free interest rate		0.41% – 3.66%		0.05% – 1.10%		0.3%
Dividend yield		—		—		—
Weighted-average grant date fair value per share	$	5.93	$	15.53	$	7.20

Schedule of Fair Value of Employee Stock Purchase Plan



	Years Ended December 31,
	2022		2021		2020
Expected term in years		0.5 - 2.0		0.5 - 2.0		0.5 - 2.0
Expected volatility		70% - 97%		67% - 68%		57% - 71%
Risk-free interest rate		0.60% - 3.51%		0.1% - 0.2%		0.1%-1.0%
Dividend yield		—		—		—
Weighted-average grant date fair value per share	$	4.28	$	25.07	$	1.87

Time-based stock options [Member]

Summary of Stock Option Activity




	Number	Weighted-average
	of shares	exercise price
Outstanding at December 31, 2021	12,159	$	11.38
Granted	5,211	$	10.34
Exercised	(1,052)	$	3.25
Canceled	(1,603)	$	19.66
Expired	(97)	$	24.26
Outstanding at December 31, 2022	14,618	$	10.60

Performance-based stock options [Member]

Summary of Stock Option Activity



	Number	Weighted-average
	of shares	exercise price
Outstanding at December 31, 2021	304	$	4.71
Granted	—	$	—
Exercised	—	$	—
Canceled	(46)	$	4.71
Outstanding at December 31, 2022	258	$	4.71

Net (Loss) Income Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Net (Loss) Income Per Share [Abstract]

Computation of Basic and Diluted Net (Loss) Income Per Share



	Years Ended December 31,
	2022		2021		2020
Numerator:
Net (loss) income	$	(314,248)	$	(181,223)	$	29,403

Denominator:
Basic
Weighted-average shares used in computing basic net (loss) income per share		224,550		204,136		165,187
Basic net (loss) income per share	$	(1.40)	$	(0.89)	$	0.18
Diluted
Weighted-average shares used in computing basic net (loss) income per share		224,550		204,136		165,187
Add: weighted-average stock options		—		—		6,092
Add: weighted-average restricted stock units		—		—		2,324
Add: weighted-average common stock issuable pursuant to our ESPP		—		—		1,367
Weighted-average shares used in computing diluted net (loss) income per share		224,550		204,136		174,970
Diluted net (loss) income per share	$	(1.40)	$	(0.89)	$	0.17

Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share



	Years Ended December 31,
(in thousands)	2022	2021	2020
Shares issuable upon conversion of convertible senior notes	20,690	20,690	—
Options to purchase common stock	14,876	12,463	4,908
RSUs with time-based vesting	8,535	7,392	100
RSUs with performance-based vesting	—	—	94
ESPP shares	3,880	1,564	2,890

Segment And Geographic Information (Tables)

12 Months Ended

Dec. 31, 2022

Segment And Geographic Information [Abstract]

Schedule of Revenue by Geographic Location



	Years Ended December 31,
(in thousands)	2022		2021		2020
Americas	$	69,561	$	64,521	$	37,277
Europe, Middle East, and Africa		22,598		30,271		19,065
Asia-Pacific		36,145		35,721		22,551
Total	$	128,304	$	130,513	$	78,893

Summary of Revenue by Category



	Years Ended December 31,
(in thousands)	2022		2021		2020
Instrument revenue	$	48,719	$	61,324	$	34,282
Consumable revenue		59,980		52,181		31,142
Product revenue		108,699		113,505		65,424
Service and other revenue		19,605		17,008		13,469
Total revenue	$	128,304	$	130,513	$	78,893

Organization and Significant Accounting Policies (Narrative) (Details)			12 Months Ended
	Dec. 31, 2022 USD ($)	Mar. 31, 2020	Dec. 31, 2022 customer	Dec. 31, 2021 customer	Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Period in which company must repay continuation advances if change-of-control transaction is entered into with third party		2 years
Fair value assets/liabilities transfer between levels \| $	$ 0
Customers with 10% or greater accounts receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| customer			1	0
Sales Revenue, Net [Member] \| Gene Company Limited [Member] \| Customer Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			12.00%	13.00%	14.00%
Accounts Receivable [Member] \| Domestic Customers [Member] \| Customer Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			57.00%	53.00%
Computer Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			3 years
Minimum [Member] \| Leasehold Improvements [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			3 years
Minimum [Member] \| Lab Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			3 years
Minimum [Member] \| Computer Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			3 years
Minimum [Member] \| Furniture And Fixtures [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			3 years
Maximum [Member] \| Leasehold Improvements [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			10 years
Maximum [Member] \| Lab Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			5 years
Maximum [Member] \| Computer Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			5 years
Maximum [Member] \| Furniture And Fixtures [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life			5 years

Business Acquisitions (Narrative) (Details) - USD ($)			12 Months Ended
Business Acquisitions (Narrative) (Details) - USD ($)	Sep. 20, 2021	Jul. 20, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Issuance of common stock in Private Placement, net of issuance costs				$ 294,845,000
Acquisition-related costs				31,129,000
Stock-based compensation expense			$ 78,613,000	80,728,000	$ 17,533,000
Goodwill			409,974,000	409,974,000
Finite-Lived Intangible Assets, Gross		$ 11,400,000	11,539,000
Income Tax Expense (Benefit)				(93,649,000)
Circulomics, Inc [Member]
Business Acquisition [Line Items]
Total cash paid		29,500,000
Goodwill		$ 19,309,000
Omniome, Inc [Member]
Business Acquisition [Line Items]
Total cash paid	$ 315,703,000
Fair value of share consideration	249,435,000
Fair value of contingent consideration	168,574,000
Contingent Consideration Incurred during period	$ 168,600,000
Issuance of common stock	8,911,580
Consideration	$ 714,789,000
Acquisition-related costs	12,000,000.0			12,000,000.0
Stock-based compensation expense	18,900,000
Income tax benefit from reduction in deferred tax assets valuation allowance	91,000,000.0
Pro forma adjustment related to acquiree's acquisition-related costs	16,700,000
Since the date of acquisition, revenues				0
Since the date of acquisition, net loss				15,600,000
Goodwill	390,665,000		410,000,000.0
Omniome, Inc [Member] \| Effect of Change Higher/(Lower) [Member]
Business Acquisition [Line Items]
Goodwill				(1,600,000)
Deferred Tax Liabilities, Deferred Expense				(400,000)
Income Tax Expense (Benefit)				$ (1,200,000)
Omniome, Inc [Member] \| Omniome stock awards related to acquisition [Member]
Business Acquisition [Line Items]
Total cash paid	7,400,000
Fair value of share consideration	6,300,000
Contingent Consideration Incurred during period	$ 5,200,000
Issuance of common stock	226,811
Consideration	$ 18,900,000
Achievement of milestone [Member] \| Omniome, Inc [Member]
Business Acquisition [Line Items]
Total cash paid	100,000,000
Fair value of share consideration	100,000,000
Fair value of contingent consideration	200,000,000
Stock options issued by PacBio in replacement of Omniome’s unvested options	$ 4,100,000
Percentage of outstanding shares of common to be issued in merger	19.90%
Issuance of common stock in Private Placement, net of issuance costs	$ 11,500,000
Developed Technology [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross			$ 11,179,000

Business Acquisitions (Schedule by Acquisitions) (Details) $ in Thousands			12 Months Ended
	Sep. 20, 2021 USD ($)	Jul. 20, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($) $ / shares	Dec. 31, 2022 USD ($)
Major classes of assets and liabilities allocated to total fair value of consideration transferred
Goodwill			$ 409,974		$ 409,974
Circulomics, Inc [Member]
Business Combination, Consideration Transferred [Abstract]
Total cash paid		$ 29,500
Major classes of assets and liabilities allocated to total fair value of consideration transferred
Cash and cash equivalents		987
Property and equipment, net		214
Intangible assets		11,360
Goodwill		19,309
Other assets		467
Deferred income tax liability		(2,672)
Liabilities assumed		(118)
Total consideration transferred		$ 29,547
Omniome, Inc [Member]
Business Combination, Consideration Transferred [Abstract]
Total cash paid	$ 315,703
Fair value of share consideration	249,435
Fair value of contingent consideration	168,574
Less: Share-based compensation expense excluded from consideration transferred	(18,923)
Total consideration transferred	714,789
Major classes of assets and liabilities allocated to total fair value of consideration transferred
Cash and cash equivalents	15,338
Property and equipment, net	6,123
Operating lease right-of-use assets, net	18,095
In-process research and development ("IPR&D")	400,000
Goodwill	390,665				$ 410,000
Other assets	3,203
Deferred income tax liability	(91,814)
Liabilities assumed	(26,821)
Total consideration transferred	$ 714,789
Business Acquisition, Pro Forma Information [Abstract]
Pro forma total revenue			130,513	$ 78,893
Pro forma net (loss) income			$ (278,451)	$ 17,510
Pro forma net (loss) income per share - basic and diluted \| $ / shares			(1.27)	0.09

Invitae Collaboration Arrangement (Narrative) (Details) - USD ($)			12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Development and Commercialization of Significant Agreements Transactions [Line Items]
Revenue			$ 128,304,000	$ 130,513,000	$ 78,893,000
Deferred revenue, current	$ 30,498,000	$ 10,977,000	30,498,000	10,977,000
Product [Member]
Development and Commercialization of Significant Agreements Transactions [Line Items]
Revenue			108,699,000	$ 113,505,000	$ 65,424,000
Invitae Corporation [Member]
Development and Commercialization of Significant Agreements Transactions [Line Items]
Revenue		$ 3,700,000
Deferred revenue, current	21,400,000		$ 21,400,000
Amount of agreement payment received upon execution	$ 23,500,000

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Termination of Merger with Illumina (Narrative) (Details) - USD ($) $ in Thousands			1 Months Ended	12 Months Ended
	Feb. 09, 2021	Mar. 31, 2020	Feb. 28, 2021	Dec. 31, 2021	Dec. 31, 2020
Merger Termination [Line Items]
(Loss) Gain from Continuation Advances			$ (52,000)	$ (52,000)	$ 34,000
Possible Continuation Advances payable		$ 52,000
Period in which company must repay continuation advances if change-of-control transaction is entered into with third party		2 years
Equity or debt financing that must be raised in a single transaction		$ 100,000
Illumina, FC Ops Corp [Member]
Merger Termination [Line Items]
(Loss) Gain from Continuation Advances		$ 52,000
Convertible Senior Notes [Member]
Merger Termination [Line Items]
Principal amount of notes	$ 900,000		$ 900,000
Debt instrument, stated interest rate	1.50%		1.50%
Maturity date	Feb. 15, 2028		Feb. 15, 2028

Financial Instruments (Narrative) (Details) - USD ($)	Dec. 31, 2022	Feb. 28, 2021	Feb. 09, 2021
Financial Instruments [Line Items]
Fair value assets/liabilities transfer between levels	$ 0
Convertible Senior Notes [Member]
Financial Instruments [Line Items]
Debt Instrument Interest Rate Stated Percentage		1.50%	1.50%
Measurement Input, Discount Rate [Member] \| Contingent consideration liability [Member] \| Maximum [Member] \| B- Credit Rating [Member]
Financial Instruments [Line Items]
Debt Instrument Interest Rate Stated Percentage	10.50%
Measurement Input, Discount Rate [Member] \| Contingent consideration liability [Member] \| Minimum [Member] \| B Credit Rating [Member]
Financial Instruments [Line Items]
Debt Instrument Interest Rate Stated Percentage	10.10%

Financial Instrument (Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash And Cash Equivalents	$ 325,089	$ 460,725
Total Investments	447,229	583,675
Short-Term Restricted Cash	300	500
Long-term restricted cash	2,922	4,592
Total assets measured at fair value	775,540	1,049,492
Liabilities
Total liabilities measured at fair value	172,094	169,717
Contingent Consideration [Member]
Liabilities
Total liabilities measured at fair value	172,094	169,717
Cash And Money Market Funds [Member]
Assets
Cash And Cash Equivalents	137,636	327,315
Commercial Paper [Member]
Assets
Cash And Cash Equivalents	166,453	133,185
U.S. Government And Agency Securities [Member]
Assets
Cash And Cash Equivalents	21,000	225
Commercial Paper, Not Included With Cash And Cash Equivalents [Member]
Assets
Total Investments	127,302	187,632
Corporate Debt Securities [Member]
Assets
Total Investments	49,491	8,968
U.S. Government & Agency Securities, Not Included With Cash And Cash Equivalents [Member]
Assets
Total Investments	270,436	387,075
Level 1 [Member]
Assets
Cash And Cash Equivalents	137,636	327,315
Short-Term Restricted Cash	300	500
Long-term restricted cash	2,922	4,592
Total assets measured at fair value	140,858	332,407
Level 1 [Member] \| Cash And Money Market Funds [Member]
Assets
Cash And Cash Equivalents	137,636	327,315
Level 2 [Member]
Assets
Cash And Cash Equivalents	187,453	133,410
Total Investments	447,229	583,675
Total assets measured at fair value	634,682	717,085
Level 2 [Member] \| Commercial Paper [Member]
Assets
Cash And Cash Equivalents	166,453	133,185
Level 2 [Member] \| U.S. Government And Agency Securities [Member]
Assets
Cash And Cash Equivalents	21,000	225
Level 2 [Member] \| Commercial Paper, Not Included With Cash And Cash Equivalents [Member]
Assets
Total Investments	127,302	187,632
Level 2 [Member] \| Corporate Debt Securities [Member]
Assets
Total Investments	49,491	8,968
Level 2 [Member] \| U.S. Government & Agency Securities, Not Included With Cash And Cash Equivalents [Member]
Assets
Total Investments	270,436	387,075
Level 3 [Member]
Liabilities
Total liabilities measured at fair value	172,094	169,717
Level 3 [Member] \| Contingent Consideration [Member]
Liabilities
Total liabilities measured at fair value	$ 172,094	$ 169,717

Financial Instruments (Changes In Estimated Fair Value Of Contingent Consideration) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in estimated fair value	$ 2,377	$ 1,143
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning balance	169,717
Change in estimated fair value	2,377
Ending balance	$ 172,094	$ 169,717

Financial Instruments (Summary of Cash, Cash Equivalents and Investments) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Total investments in debt securities	$ 634,682,000
Cash, cash equivalents and investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	777,083,000	$ 1,045,488,000
Gross unrealized gains	16,000	10,000
Gross unrealized losses	(4,781,000)	(1,097,000)
Total investments in debt securities	772,318,000	1,044,400,000
Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	325,144,000	460,731,000
Gross unrealized gains	6,000
Gross unrealized losses	(61,000)	(5,000)
Total investments in debt securities	325,089,000	460,725,000
Cash And Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	137,636,000	327,316,000
Total investments in debt securities	137,636,000	327,316,000
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	166,514,000	133,190,000
Gross unrealized losses	(61,000)	(5,000)
Total investments in debt securities	166,453,000	133,185,000
U.S. Government And Agency Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	20,994,000	225,000
Gross unrealized gains	6,000
Total investments in debt securities	21,000,000	224,000
Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	451,939,000	584,757,000
Gross unrealized gains	10,000	10,000
Gross unrealized losses	(4,720,000)	(1,092,000)
Total investments in debt securities	447,229,000	583,675,000
Commercial Paper, Not Included With Cash And Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	127,626,000	187,705,000
Gross unrealized gains	9,000
Gross unrealized losses	(333,000)	(73,000)
Total investments in debt securities	127,302,000	187,632,000
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	49,998,000	8,964,000
Gross unrealized gains		9,000
Gross unrealized losses	(507,000)	(5,000)
Total investments in debt securities	49,491,000	8,968,000
U.S. Government & Agency Securities, Not Included With Cash And Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	274,315,000	388,088,000
Gross unrealized gains	1,000	1,000
Gross unrealized losses	(3,880,000)	(1,014,000)
Total investments in debt securities	270,436,000	387,075,000
Long-Term Restricted Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	2,922,000	4,592,000
Total investments in debt securities	2,922,000	4,592,000
Short-Term Restricted Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	300,000	500,000
Total investments in debt securities	$ 300,000	$ 500,000

Financial Instruments (Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments) (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Cash, Cash Equivalents and Investments [Abstract]
Due in one year or less	$ 564,752
Due after one year through five years	69,930
Total investments	$ 634,682

Balance Sheet Components (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Sep. 20, 2021
Balance Sheet Components [Line Items]
Percentage of fee to prepay debt		4.00%
Long-term restricted cash		$ 2,922,000	$ 4,592,000
Goodwill		409,974,000	409,974,000
Amortization of intangible assets		900,000	400,000	$ 0
Depreciation		9,480,000	7,199,000	6,428,000	$ 6,400,000
Inventory reserves		6,027,000	678,000	$ 527,000
Deferred revenue, current		30,498,000	10,977,000
Deferred revenue, non-current		1,794,000	25,049,000
Prepaid expenses and other current assets		10,289,000	$ 7,394,000
Notes Payable		2,300,000
Notes payable, current		1,800,000
Long Term Notes Payable		500,000
Interest Expense		$ 600,000
Standard Product Warranty Description		one-year warranty on instruments
Omniome, Inc [Member]
Balance Sheet Components [Line Items]
Goodwill		$ 410,000,000.0				$ 390,665,000
Short term debt acquired	$ 1,300,000
Long-term debt acquired	$ 3,000,000.0
Debt Instrument, Term	43 months
Debt Instrument Interest Rate Stated Percentage	17.00%
Omniome, Inc [Member] \| In-process research and development indefinite lived [Member]
Balance Sheet Components [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 400,000,000
Service [Member]
Balance Sheet Components [Line Items]
Deferred revenue		32,300,000
Deferred revenue, current		30,500,000
Deferred revenue, non-current		1,800,000
Revenue recognized		$ 13,000,000.0
Deferred service revenue, noncurrent, recognition period		6 years
Invitae Corporation [Member]
Balance Sheet Components [Line Items]
Deferred revenue, current		$ 21,400,000

Balance Sheet Components (Components of Inventory) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Purchased materials	$ 24,139	$ 7,993
Work in process	14,062	8,611
Finished goods	12,180	7,995
Inventory	$ 50,381	$ 24,599

Balance Sheet Components (Components of Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment	$ 106,568	$ 88,790
Less: Accumulated depreciation	(64,988)	(56,286)
Property and equipment, net	41,580	32,504
Laboratory Equipment And Machinery [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	38,998	31,534
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	34,129	31,114
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	18,438	15,059
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	6,879	5,578
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	3,426	3,202
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 4,698	$ 2,303

Balance Sheet Components (Definite-lived Intangible Assets from Business Acquisitions) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Jul. 20, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 11,539,000	$ 11,400,000
Accumulated Amortization	(1,294,000)
Net Carrying Amount	$ 10,245,000
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in years)	15 years
Gross Carrying Amount	$ 11,179,000
Accumulated Amortization	(1,039,000)
Net Carrying Amount	$ 10,140,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in years)	2 years
Gross Carrying Amount	$ 360,000
Accumulated Amortization	(255,000)
Net Carrying Amount	$ 105,000

Balance Sheet Components (Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives) (Details)	Dec. 31, 2022 USD ($)
Balance Sheet Components [Abstract]
2023	$ 853,000
2024	745,000
2025	745,000
2026	745,000
2027	746,000
2028 and thereafter	6,411,000
Total	$ 10,245,000

Balance Sheet Components (Accrued Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Salaries and benefits	$ 17,432	$ 25,282
Accrued interest payable	5,100	5,100
Accrued purchase commitments	3,705
Accrued product development costs	2,326	1,936
Accrued professional services and legal fees	1,005	1,640
Inventory accrual	332	108
Warranty	1,651	594
Other	1,045	1,601
Accrued expenses	$ 32,596	$ 36,261

Balance Sheet Components (Changes in Reserve for Product Warranties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Balance at beginning of period	$ 594	$ 161
Additions charged to cost of product revenue	3,199	2,120
Repairs and replacements	(2,142)	(1,687)
Balance at end of period	$ 1,651	$ 594

Balance Sheet Components (Future Principal Payments , Fiscal Year Maturity) (Details)	Dec. 31, 2022 USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt	$ 896,683,000
Omniome, Inc [Member]
Long-term Debt, Fiscal Year Maturity [Abstract]
2023	1,842,000
2024	490,000
Long-term Debt	$ 2,332,000

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Balance Sheet Components (Other Liabilities, Current) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Accrued Employee Stock Purchase Plan	$ 3,638	$ 3,598
Short-term loan	1,842	1,608
Other	1,753	553
Other liabilities, current	$ 7,233	$ 5,759

Convertible Senior Notes (Narrative) (Details) - Convertible Senior Notes [Member] - USD ($)			1 Months Ended	12 Months Ended
	Feb. 16, 2021	Feb. 09, 2021	Feb. 28, 2021	Dec. 31, 2022
Debt Instrument [Line Items]
Principal amount of notes		$ 900,000,000	$ 900,000,000
Debt instrument, stated interest rate		1.50%	1.50%
Maturity date		Feb. 15, 2028	Feb. 15, 2028
Issuance date				Feb. 16, 2021
Shares issued conversion rate per $1,000 principal amount	22.9885
Principal amount for conversion rate	$ 1,000
Conversion price per share	$ 43.50
Debt redemption, percentage of conversion price	150.00%
Debt redemption, trading days	20 days
Debt redemption, consecutive trading days	30 days
Redemption price, percentage	100.00%
Debt issuance costs				$ 4,500,000
Debt instrument, effective interest rate				1.60%
Fair value of convertible debt				$ 604,800,000
Each Day During the First 180 Days [Member]
Debt Instrument [Line Items]
Additional interest in the event of default	0.25%
181st Day to 360th Day [Member]
Debt Instrument [Line Items]
Additional interest in the event of default	0.50%

Convertible Senior Notes (Net Carrying Amount) (Details)	Dec. 31, 2022 USD ($)
Convertible Senior Notes [Abstract]
Principal amount	$ 900,000,000
Unamortized debt issuance costs	(3,317,000)
Net carrying amount	$ 896,683,000

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Convertible Senior Notes (Interest Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Convertible Senior Notes [Abstract]
Contractual interest expense	$ 13,500	$ 11,812
Amortization of debt issuance costs	617	532
Total interest expense	$ 14,117	$ 12,344

Commitments and Contingencies (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 20, 2021
Commitments and Contingencies [Line Items]
Operating Lease, Right-of-Use Asset			$ 39,763,000	$ 46,617,000
Weighted average remaining lease term			4 years 8 months 12 days
Weighted average discount rate			6.70%
Rent payments			$ 11,200,000	8,200,000
Operating lease cost			10,500,000	$ 7,200,000
Purchase Obligation			145,700,000
Additional liability associated with indemnification obligations			0
Operating Lease, Liability			49,956,000
Payments for Deposits	$ 9,000,000.0
Deposit in other long-term assets			9,000,000.0
Loss on purchase commitment			$ 3,700,000
Omniome, Inc [Member]
Commitments and Contingencies [Line Items]
Operating Lease, Right-of-Use Asset					$ 18,100,000
Operating Lease, Liability					$ 18,100,000
Forecast [Member]
Commitments and Contingencies [Line Items]
Payments for Deposits		$ 6,000,000.0
Deposit in other long-term assets		$ 15,000,000.0

Commitments and Contingencies (Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Maturity of Lease Liabilities
2023	$ 11,955
2024	12,018
2025	12,279
2026	12,392
2027	9,930
Total undiscounted operating lease payments	58,574
Less: imputed interest	(8,618)
Present value of operating lease liabilities	49,956
Balance Sheet Classification
Operating lease liabilities, current	8,886	$ 7,710
Operating lease liabilities, non-current	41,070	$ 49,970
Total operating lease liabilities	$ 49,956

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Income (loss) before taxes from U.S. operations	$ (315,700)	$ (275,400)	$ (28,900)
Income before taxes from foreign operations	$ 1,800	$ 800	$ 600
Statutory tax rate	21.00%	21.00%	21.00%
Valuation allowance	$ 445,574	$ 366,940
Net operating loss carryforwards	400,600
Research and development credit carryforward	71,500
Total unrecognized tax benefit	$ 10,410	8,335	$ 5,954	$ 21,979
Probability of benefit Realized Upon Settlement Uncertain Tax Position	50.00%
Accrued interest or penalties		$ 0	$ 0
Probability of benefit Realized Upon Settlement Uncertain Tax Position	50.00%
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 1,573,800
Research and development credit carryforward	$ 47,200
Research and development tax credit carryforward, expiration	2024
Benefit of federal net operating loss deferred tax assets	$ 1,573,800
Federal [Member] \| With Expiration [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	774,900
State [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	1,071,800
Benefit of state net operating loss deferred tax assets	1,071,800
State [Member] \| No Expiration [Member]
Income Taxes [Line Items]
Research and development credit carryforward	$ 42,600
Minimum [Member] \| Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforward, expiration	2024

Income Taxes (Reconciliation of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Statutory tax rate	21.00%	21.00%	21.00%
State tax rate, net of federal benefit	4.40%	5.50%	(8.30%)
Change in valuation allowance	(25.10%)	(4.90%)	6.30%
Tax credits	2.20%	2.50%	(3.60%)
Stock-based compensation	(2.20%)	10.90%	(15.20%)
Merger Expenses		(0.9)
Other	(0.40%)	(0.10%)	(0.20%)
Total	(0.10%)	34.00%

Income Taxes (Reconciliation of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 400,629	$ 378,035
Research and development credits	71,526	60,672
Capitalized research and experimental expenses	34,863
Accruals and reserves	18,417	10,822
Stock-based compensation	17,117	12,838
ASC842 Operating lease liability	11,537	13,105
Total deferred tax assets	554,089	475,472
Less: Valuation allowance	(445,574)	(366,940)
Total deferred tax assets:	108,515	108,532
Intangibles	(98,931)	(97,345)
Fixed assets	(1,262)	(1,523)
ASC 842 Operating Lease right-of-use assets	(9,157)	(10,502)
Total deferred tax liabilities	(109,350)	(109,370)
Net deferred tax liabilities	$ (835)	$ (838)

Income Taxes (Reconciliation of Unrecognized Tax Benefit Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Unrecognized tax benefit, Beginning balance	$ 8,335	$ 5,954	$ 21,979
Increase in balance related to tax positions taken in prior year		189
Decrease in balance related to tax positions taken in prior year	(10)		(17,255)
Increase in balance related to tax positions taken during current year	2,085	2,192	1,230
Unrecognized tax benefit, Ending balance	$ 10,410	$ 8,335	$ 5,954

Stockholders' Equity (Narrative) (Details) $ / shares in Units, $ in Thousands						1 Months Ended		12 Months Ended
	Jan. 27, 2023 USD ($) $ / shares shares	May 22, 2022 shares	Nov. 22, 2021 shares	Sep. 20, 2021 USD ($) item $ / shares shares	Apr. 18, 2021 shares	Nov. 30, 2020 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) item $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares item shares	Dec. 02, 2020 shares	Aug. 04, 2020 shares	Oct. 31, 2010 $ / shares shares
Stockholders' Equity [Line Items]
Common Stock Shares Authorized								1,000,000,000	1,000,000,000				1,000,000,000
Common Stock Par Or Stated Value Per Share \| $ / shares								$ 0.001	$ 0.001				$ 0.001
Preferred Stock Shares Authorized								50,000,000	50,000,000				50,000,000
Preferred Stock Par Or Stated Value Per Share \| $ / shares								$ 0.001	$ 0.001				$ 0.001
Preferred Stock Shares Issued								0	0
Preferred Stock Shares Outstanding								0	0
Common stock, dividends declared \| $ / shares								$ 0
Voting right of common stock share holders								one
Voting right of common stock share holders, number of votes \| item								1
Proceeds From Issuance Of Common Stock \| $								$ 11,230	$ 31,806	$ 46,360
Vested and exercisable options								22,700,000
Weighted average remaining contractual life for exercisable								5 years 4 months 24 days
Vested and expected to vest, aggregate intrinsic value \| $								$ 24,600
Vested and expected to vest, weighted average exercise price \| $ / shares								$ 10.61
Vested and expected to vest, weighted average remaining contractual life								6 years 6 months
Total intrinsic value of options exercised \| $								$ 5,000	146,100	$ 63,100
Stock-based compensation cost capitalized in inventory \| $								$ 700	$ 900
Dividend yield								0.00%
Weighted average grant date fair value per share \| $ / shares								$ 5.93	$ 18.36	$ 4.14
Common Stock Shares Issued								226,505,000	220,978,000
Private Placement of Common Stock [Member]
Stockholders' Equity [Line Items]
Proceeds From Issuance Of Common Stock \| $				$ 300,000
Price per share \| $ / shares				$ 26.75
Common Stock Shares Issued				11,214,953
Common Stock [Member]
Stockholders' Equity [Line Items]
Shares issued										29,356,000
Omniome Plan [Member]
Stockholders' Equity [Line Items]
Exchange ratio \| item				0.259204639
Shares authorized				2,494,128
2010 Plan [Member]
Stockholders' Equity [Line Items]
Common stock remain available for issuance								25,500,000
ESPP [Member]
Stockholders' Equity [Line Items]
Common stock remain available for issuance								9,932,505
Percentage of outstanding common stock used to determine annual plan increase								2.00%
Number of purchase periods \| item								4
Purchase period of ESPP								6 months
Percentage of fair market value at which stock can be purchased								85.00%
Common stock purchased under plan								1,878,168	1,913,968	834,677
Cash received from option exercises \| $								$ 7,800	$ 6,400	$ 2,400
Weighted-average grant-date fair value of all RSUs granted \| $ / shares								$ 4.28	$ 25.07	$ 1.87
Common Stock Shares Issued								4,000,000
2020 Equity Incentive Plan [Member]
Stockholders' Equity [Line Items]
Shares authorized												11,000,000
Additional common stock reserved for issuance		18,000,000
2020 Inducement Equity Incentive Plan [Member]
Stockholders' Equity [Line Items]
Shares authorized											2,500,000
Additional common stock reserved for issuance			360,000		750,000
Common stock remain available for issuance								18,900,000
Underwritten Public Equity Offering [Member]
Stockholders' Equity [Line Items]
Shares issued										29,400,000
Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs \| $										$ 187,200
Number of offerings \| item								2		2
Price per share \| $ / shares										$ 6.40
Underwriting Agreement [Member]
Stockholders' Equity [Line Items]
Common Stock Par Or Stated Value Per Share \| $ / shares						$ 0.001	$ 0.001
Public offering						6,096,112	19,430,000
Common stock offering price per share \| $ / shares						$ 14.25	$ 4.47
Public offering, option to purchase additional shares, period						30 days	30 days
Public offering, option to purchase additional shares, shares						914,416	2,914,500
Shares issued						7,000,000.0	22,300,000
Commissions, percentage of gross proceeds						6.00%	6.00%
Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs \| $						$ 93,900	$ 93,900
Offering costs \| $						$ 300	$ 300
Time-based and performance-based options [Member]
Stockholders' Equity [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number								9,408,063
Options expired, weighted average exercise price \| $ / shares								$ 8.45
Aggregate intrinsic value outstanding \| $								$ 24,700
Weighted average remaining contractual life								6 years 8 months 12 days
Vested and expected to vest, outstanding								14,436,695
RSUs With Time-Based Vesting [Member]
Stockholders' Equity [Line Items]
Ratio of number of shares into which the share instrument may be converted								1
Vesting period								4 years
Weighted-average grant-date fair value of all RSUs granted \| $ / shares								$ 10.15	$ 35.33	$ 5.18
Total fair value of shares vested related to RSUs \| $								$ 39,200	$ 9,200	$ 6,300
Options To Purchase Common Stock [Member]
Stockholders' Equity [Line Items]
Stock price \| $ / shares								$ 8.18
Unrecognized compensation costs \| $								$ 125,100
Cash received from option exercises \| $								$ 3,400	$ 25,400	$ 43,900
Weighted average grant date fair value per share \| $ / shares								$ 5.93	$ 15.53	$ 7.20
Options To Purchase Common Stock [Member] \| Common Stock [Member]
Stockholders' Equity [Line Items]
Weighted average remaining contractual life								2 years 4 months 24 days
Subsequent Event [Member]
Stockholders' Equity [Line Items]
Proceeds From Issuance Of Common Stock \| $	$ 201,300
Price per share \| $ / shares	$ 10.00
Common Stock Shares Issued	20,125,000
Share-based Compensation Award, Tranche One, Two, Three and Four [Member] \| RSUs With Time-Based Vesting [Member]
Stockholders' Equity [Line Items]
Vesting percentage								25.00%

Stockholders' Equity (Summary of Stock Option Activity) (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Time-based stock option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares, Outstanding, Beginning \| shares	12,159,000
Number of shares, Granted \| shares	5,211,000
Number of shares, Exercised \| shares	(1,052,000)
Number of shares, Canceled \| shares	(1,603,000)
Number of shares, Expired \| shares	(97,000)
Number of shares, Outstanding, Ending \| shares	14,618,000
Weighted average exercise price, Outstanding, Beginning \| $ / shares	$ 11.38
Weighted average exercise price, Granted \| $ / shares	10.34
Weighted average exercise price, Exercised \| $ / shares	3.25
Weighted average exercise price, Canceled \| $ / shares	19.66
Weighted average exercise price, Expired \| $ / shares	24.26
Weighted average exercise price, Outstanding, Ending \| $ / shares	$ 10.60
Performance-based stock options [Member] \| Omniome Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares, Outstanding, Beginning \| shares	304,000
Number of shares, Canceled \| shares	(46,000)
Number of shares, Outstanding, Ending \| shares	258,000
Weighted average exercise price, Outstanding, Beginning \| $ / shares	$ 4.71
Weighted average exercise price, Canceled \| $ / shares	4.71
Weighted average exercise price, Outstanding, Ending \| $ / shares	$ 4.71

Stockholders' Equity (Summary of Time-Based RSUs Activity) (Details) - RSUs With Time-Based Vesting [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Outstanding, Beginning	7,392
Number of shares, Granted	5,389
Number of shares, Released	(2,582)
Number of shares, Forfeited	(1,664)
Number of shares, Outstanding, Ending	8,535	7,392
Weighted average grant date fair value Outstanding, Beginning	$ 19.78
Weighted average grant date fair value, Granted	10.15	$ 35.33	$ 5.18
Weighted average grant date fair value, Released	15.19
Weighted average grant date fair value, Forfeited	19.42
Weighted average grant date fair value, Outstanding Ending	$ 15.16	$ 19.78

Stockholders' Equity (Schedule of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 78,613	$ 80,728	$ 17,533
Cost of revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	4,802	6,126	2,236
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	30,676	20,275	7,061
Sales, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	43,135	35,403	8,236
Merger-related expenses - stock-settled [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense		6,349
Merger-related expenses - milestone [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense		5,202
Share-based compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 78,613	73,355	$ 17,533
Merger-related expenses - cash-settled [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense		$ 7,373

Stockholders' Equity (Schedule of Fair Value of Employee Stock Options) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Weighted average grant date fair value per share	$ 5.93	$ 18.36	$ 4.14
Options To Purchase Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years			5 years
Expected volatility			70.70%
Risk-free interest rate			0.30%
Risk-free interest rate, minimum	0.41%	0.05%
Risk-free interest rate, maximum	3.66%	1.10%
Weighted average grant date fair value per share	$ 5.93	$ 15.53	$ 7.20
Options To Purchase Common Stock [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	4 years 7 months 6 days	2 years 1 month 6 days
Expected volatility	70.00%	67.00%
Options To Purchase Common Stock [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years		4 years 7 months 6 days
Expected volatility	76.00%	80.00%

Stockholders' Equity (Schedule of Fair Value of Employee Stock Purchase Plan) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.60%	0.10%	0.10%
Risk-free interest rate, maximum	3.51%	0.20%	1.00%
Weighted average grant date fair value, Granted	$ 4.28	$ 25.07	$ 1.87
ESPP [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 months	6 months	6 months
Expected volatility	70.00%	67.00%	57.00%
ESPP [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	2 years	2 years	2 years
Expected volatility	97.00%	68.00%	71.00%

Net Loss Per Share (Computation of Basic and Diluted Net (Loss) Income Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator
Net (loss) income	$ (314,248)	$ (181,223)	$ 29,403
Basic
Weighted-average shares used in computing basic net (loss) income per share	224,550	204,136	165,187
Basic net (loss) income per share	$ (1.40)	$ (0.89)	$ 0.18
Diluted
Weighted-average shares used in computing basic net (loss) income per share	224,550	204,136	165,187
Weighted-average shares used in computing diluted net (loss) income per share	224,550	204,136	174,970
Diluted net (loss) income per share	$ (1.40)	$ (0.89)	$ 0.17
Options To Purchase Common Stock [Member]
Diluted
Add: weighted average			6,092
RSUs [Member]
Diluted
Add: weighted average			2,324
ESPP [Member]
Diluted
Add: weighted average			1,367

Net Loss Per Share (Antidilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details) - shares shares in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shares Issuable Upon Conversion Of Convertible Senior Notes [Member] [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share	20,690	20,690
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share	14,876	12,463	4,908
RSUs With Time-Based Vesting [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share	8,535	7,392	100
RSUs With Performance-Based Vesting [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share			94
ESPP [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share	3,880	1,564	2,890

Segment And Geographic Information (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022 segment
Segment And Geographic Information [Abstract]
Number of reportable segments	1

Segment And Geographic Information (Schedule of Revenue by Geographic Location) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 128,304,000	$ 130,513,000	$ 78,893,000
Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	69,561,000	64,521,000	37,277,000
Europe, Middle East And Africa [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	22,598,000	30,271,000	19,065,000
Asia-Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 36,145,000	$ 35,721,000	$ 22,551,000

- Definition

+ References

+ Details

Segment And Geographic Information (Summary of Revenue by Category) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 128,304,000	$ 130,513,000	$ 78,893,000
Product [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	108,699,000	113,505,000	65,424,000
Instrument [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	48,719,000	61,324,000	34,282,000
Consumable [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	59,980,000	52,181,000	31,142,000
Service and Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 19,605,000	$ 17,008,000	$ 13,469,000

- Definition

+ References

+ Details

Subsequent Events (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jan. 27, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Oct. 31, 2010
Subsequent Events [Line Items]
Common Stock, shares issued		226,505,000	220,978,000
Common Stock, par value		$ 0.001	$ 0.001		$ 0.001
Proceeds from issuance of common stock		$ 11,230	$ 31,806	$ 46,360
Subsequent Event [Member]
Subsequent Events [Line Items]
Common Stock, shares issued	20,125,000
Price per share	$ 10.00
Proceeds from issuance of common stock	$ 201,300